Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2021 Oct 2;96:105098. doi: 10.1016/j.meegid.2021.105098

Association of Vitamin D receptor gene polymorphisms and clinical/severe outcomes of COVID-19 patients

Rasoul Abdollahzadeh a,⁎,1, Mohammad Hossein Shushizadeh b,1, Mina Barazandehrokh c, Sepideh Choopani d, Asaad Azarnezhad e,, Sahereh Paknahad a, Maryam Pirhoushiaran a, S Zahra Makani f, Razieh Zarifian Yeganeh a, Ahmed Al-Kateb g, Roozbeh Heidarzadehpilehrood h
PMCID: PMC8487094  PMID: 34610433

Abstract

Introduction

Growing evidence documented the critical impacts of vitamin D (VD) in the prognosis of COVID-19 patients. The functions of VD are dependent on the vitamin D receptor (VDR) in the VD/VDR signaling pathway. Therefore, we aimed to assess the association of VDR gene polymorphisms with COVID-19 outcomes.

Methods

In the present study, eight VDR single nucleotide polymorphisms (SNPs) were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 500 COVID-19 patients in Iran, including 160 asymptomatic, 250 mild/moderate, and 90 severe/critical cases. The association of these polymorphisms with severity, clinical outcomes, and comorbidities were evaluated through the calculation of the Odds ratio (OR).

Results

Interestingly, significant associations were disclosed for some of the SNP-related alleles and/or genotypes in one or more genetic models with different clinical data in COVID-19 patients. Significant association of VDR-SNPs with signs, symptoms, and comorbidities was as follows: ApaI with shortness of breath (P ˂ 0.001) and asthma (P = 0.034) in severe/critical patients (group III); BsmI with chronic renal disease (P = 0.010) in mild/moderate patients (group II); Tru9I with vomiting (P = 0.031), shortness of breath (P = 0.04), and hypertension (P = 0.030); FokI with fever and hypertension (P = 0.027) in severe/critical patients (group III); CDX2 with shortness of breath (P = 0.022), hypertension (P = 0.036), and diabetes (P = 0.042) in severe/critical patients (group III); EcoRV with diabetes (P ˂ 0.001 and P = 0.045 in mild/moderate patients (group II) and severe/critical patients (group III), respectively). However, the association of VDR TaqI and BglI polymorphisms with clinical symptoms and comorbidities in COVID-19 patients was not significant.

Conclusion

VDR gene polymorphisms might play critical roles in the vulnerability to infection and severity of COVID-19, probably by altering the risk of comorbidities. However, these results require further validation in larger studies with different ethnicities and geographical regions.

Keywords: COVID-19, Vitamin D receptor, Single nucleotide polymorphisms (SNPs), Genetic predisposition, Clinical outcomes

1. Introduction

The ongoing global epidemic of coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, certainly represents one of the most important clinical emergencies of the 21st century (Sohrabi et al., 2020; De Wit et al., 2016). COVID-19 can manifest a wide spectrum of clinical symptoms, which range from lack of symptoms, or mild symptoms of the upper respiratory tract to severe pneumonia with acute respiratory distress syndrome (ARDS) and death (Richardson et al., 2020; Grasselli et al., 2020). This highly phenotypic heterogeneity seems to depend on patient age, gender, underlying health conditions, and inter-individual genetic unevenness (Xie and Chen, 2020). Vitamin D (VD) has been demonstrated to perform critical roles in a wide range of immunomodulatory, anti-inflammatory, antifibrotic, and antioxidant functions. Therefore, its deficiency and insufficiency contribute to many pathogenic conditions, including autoimmune disorders, respiratory infections, cancer, cardiovascular disorders, osteoporosis, sarcopenia, and diabetes (Bizzaro et al., 2017; Kunadian et al., 2014; Amrein et al., 2020; Zdrenghea et al., 2017). There is growing evidence to indicate that VD insufficiency is strongly associated with an increased risk of acquiring COVID-19 infection (Meltzer et al., 2020), as well as developing COVID-19-associated thrombosis (Weir et al., 2020). Furthermore, VD deficiency was demonstrated to be a fatal co-morbidity in COVID-19 patients (Biesalski, 2020). On the other hand, mounting investigations declare that VD supplementation, especially FDA-approved analog (generic name, paricalcitol), prevents COVID-19 infection-induced multi-organ damage (Aygun, 2020), coagulopathy (Ali, 2020), mortality (Grant et al., 2020; Ilie et al., 2020), as well as attenuates the risk and severity of COVID-19 (Hribar et al., 2020). Therefore it has been postulated that daily supplementation with moderate doses of vitamin D3 is a safe treatment for COVID-19 patients (Zemb et al., 2020).

The mechanisms by which VD insufficiency exacerbates COVID-19-associated pneumonia remain poorly understood. However, most studies have focused on the pivotal roles of the VD/VD receptor (VDR) pathway in alleviating acute lung injury (ALI) and ARDS, a crucial component of the pathophysiological processes that occurred in almost 20% of the hospitalized patients (including ICU and non-ICU patients) with COVID-19 (Xu et al., 2020; Chen et al., 2020). The two principal pathophysiological mechanisms involved in ARDS include the release of large amounts of pro-inflammatory cytokines and chemokines, known as a cytokine storm, and aberrant activation of the renin-angiotensin system (RAS) with a decrease of angiotensin-converting enzyme2 (ACE2) (Channappanavar and Perlman, 2017; Cameron et al., 2008; Imai et al., 2005). Most previous work has revealed that the VD/VDR signaling axis may provide some beneficial effects in COVID-19 infection and especially in related ARDS phenotype through several mechanisms, such as attenuating the storm of cytokines and chemokines, modulating of the RAS, regulating the activity of a wide range of the immune cell types i.e., neutrophil and monocytes/macrophages, maintaining the integrity of the pulmonary epithelial barrier and stimulating epithelial repair, declining coagulation and thrombosis, and attenuating endothelial dysfunction (Xu et al., 2017; Shi et al., 2016; Kong et al., 2013; Zheng et al., 2020; Zhang et al., 2020a).

VDR exerts its pleiotropic effects via binding with its active ligand, vitamin D, 1α,25-dihydroxy vitamin D3 [1,25(OH)2D3], and functions as a transcription factor (TF) on ~5% of human genes through binding to more than 23,000 cell-specific genomic locations, known as vitamin D response elements (VDREs) (Tuoresmäki et al., 2014; Rhodes et al., 2020). The VDR gene is mapped at chromosome 12q13.11 which spans ~100 kb and has five promoters, eight coding exons, and six untranslated exons (K-i et al., 1997). Genetic variations in the VDR gene such as single nucleotide polymorphisms (SNPs) might influence the activity, stability, and expression levels of VDR products (mRNAs and/or proteins), subsequently altering the VD-VDR signaling axis, ultimately leading to disturbance of VD immune-regulatory functions. To date, a vast amount of investigations have been accomplished regarding the association of VDR polymorphisms with susceptibility to different diseases, including autoimmune disorders, cancers, viral and bacterial respiratory infections (Valdivielso and Fernandez, 2006; Laplana et al., 2018; Abdollahzadeh et al., 2016; Abdollahzadeh et al., 2018). Collectively, a few VDR gene variants that have been observed in relation to predisposing to various conditions with contradictory results include ApaI (rs7975232; intron 8; C > A), BsmI (rs1544410; intron 8; G > A), Tru9I (rs757343; intron 8; G > A), TaqI (rs731236; exon 9; A > G), BglI (rs739837; 3′UTR region; C > T), FokI (rs2228570; exon 2; C > T), CDX2 (rs11568820; promoter; G > A), and EcoRV or A-1012G/GATA (rs4516035; promoter; T > C). Hence, we aimed to evaluate the potential association of the aforementioned eight SNPs located in the 5′ end (FokI, CDX2, and EcoRV) and also 3'end (ApaI, BsmI, Tru9I, TaqI, and BglI) of the VDR gene with the severity of COVID-19 in an Iranian population. The identification of genetic variants linked with variable susceptibility of individuals to COVID-19 infection and severity of adverse complications could ultimately help open new avenues, including innovative personalized treatments, stratifying individuals according to the risk, and prioritization of subjects at greater risk for protection, assisting current biomedical research efforts to combat the virus, and also guide current genetics and genomics research towards candidate gene variants that warrant further investigation in larger studies.

2. Material and methods

2.1. COVID-19 patients

Five hundred COVID-19 patients were recruited in the current study that hospitalized at several different hospitals (Iran), during the period between May 5 and September 25, 2020. The COVID-19 diagnoses were established based on a positive result of real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay of nasal and/or pharyngeal swabs, following WHO interim guidance (Organization WH, 2020). The enrolled patients were categorized into 3 groups based on clinical manifestations: group I, 160 asymptomatic subjects, according to the absence of clinical symptoms and no need for hospitalization or ventilation; group II, 250 mild/moderate patients with a wide range of symptoms, including fever, sore throat, dry cough, headache, shortness of breath, diarrhea, myalgia, fatigue, nausea, vomiting, and parageusia; and group III, 90 subjects with a severe/critical condition. Regarding respiratory impairment, severe cases require non-invasive ventilation, while critical patients, defined as respiratory failure, requiring invasive ventilation and intensive care unit (ICU) admission. The presence of comorbidities (hypertension, diabetes, asthma, cardiovascular disease, chronic renal disease, and malignancy) was obtained from the participant's medical records (Table 1 ). The current research was conducted in agreement with the ethical principles of the Declaration of Helsinki and all the patients or their representatives gave their consent to participate.

Table 1.

Baseline features of COVID-19 participants.

Variables
Status
Asymptomatic patients (group I)
Mild/moderate illness (group II)
Severe and critical illness (group III)
P- value (I and II) P- value (I and III) P- value (II and III) Overall P- value
Number (%) 500 (100.0) 160 (32.0) 250 (50.0) 90 (18.0)
Age (mean ± Std. Deviation) 53.30 ± 16.16 50.28 ± 16.76 53.10 ± 16.10 59.19 ± 13.62 0.187 ˂ 0.001 0.006 ˂ 0.001
Gender Male 293 (58.60) 90 (56.3) 142 (56.8) 61 (67.8) 0.988 0.090 0.069 0.161
Female 207 (41.40) 70 (43.7) 108 (43.2) 29 (32.2)



Signs and symptoms
Variables Status Asymptomatic patients (group I) Mild/moderate illness (group II) Severe and critical illness (group III) P- value (II and III)
Fever Yes 0 (0.0) 141 (56.4) 52 (57.8) 0.821
No 160 (100.0) 109 (43.6) 38 (42.2)
Sore throat Yes 0 (0.0) 82 (32.8) 26 (28.9) 0.494
No 160 (100.0) 168 (67.2) 64 (71.1)
Dry cough Yes 0 (0.0) 144 (57.6) 44 (48.9) 0.154
No 160 (100.0) 106 (42.4) 46 (51.1)
Headache Yes 0 (0.0) 49 (19.6) 10 (11.1) 0.068
No 160 (100.0) 201 (80.4) 80 (88.9)
Shortness of breath Yes 0 (0.0) 32 (12.8) 58 (64.4) ˂ 0.001
No 160 (100.0) 218 (87.2) 32 (35.6)
Diarrhea Yes 0 (0.0) 19 (7.6) 11 (12.2) 0.185
No 160 (100.0) 231 (92.4) 79 (87.8)
Myalgia Yes 0 (0.0) 62 (24.8) 17 (18.9) 0.255
No 160 (100.0) 188 (75.2) 73 (81.1)
Fatigue Yes 0 (0.0) 26 (10.4) 31 (34.4) ˂ 0.001
No 160 (100.0) 224 (89.6) 59 (56.6)
Nausea Yes 0 (0.0) 24 (9.6) 15 (16.7) 0.071
No 160 (100.0) 226 (90.4) 75 (83.3)
Vomiting Yes 0 (0.0) 18 (7.2) 11 (12.2) 0.144
No 160 (100.0) 232 (92.8) 79 (87.8)
Parageusia Yes 0 (0.0) 12 (4.8) 26 (28.9) ˂ 0.001
No 160 (100.0) 238 (95.2) 64 (71.1)



Comorbidities
Variables Status Asymptomatic patients (group I) Mild/moderate illness (group II) Severe and critical illness (group III) P- value (I and II) P- value (I and III) P- value (II and III) Overall P- value
Hypertension Yes 19 (11.9) 44 (17.6) 45 (50.0) 0.117 ˂ 0.001 ˂ 0.001 ˂ 0.001
No 141 (88.1) 206 (82.4) 45 (50.0)
OR (95% CI)III vs. I = 7.42 (3.94–13.97), OR (95% CI)III vs. II = 4.68 (2.77–7.92)
Diabetes Yes 16 (10.0) 44 (17.6) 32 (35.6) 0.034 ˂ 0.001 ˂ 0.001 ˂ 0.001
No 144 (90.0) 206 (82.4) 58 (64.4)
OR (95% CI)II vs. I = 1.92 (1.04–3.54), OR (95% CI)III vs. I = 4.97 (2.53–9.73), OR (95% CI)III vs. II = 2.58 (1.50–4.44)
Asthma Yes 22 (13.8) 14 (5.6) 15 (16.7) 0.002 ˂ 0.001 0.001 ˂ 0.001
No 138 (86.2) 236 (94.4) 75 (83.3)
OR (95% CI)II vs. I = 0.37 (0.18–0.75), OR (95% CI)III vs. II = 3.37 (1.56–7.31)
Cardiovascular disease Yes 18 (11.2) 24 (9.6) 11 (12.2) 0.591 0.818 0.483 0.746
No 142 (88.8) 226 (90.4) 79 (87.8)
Chronic renal disease Yes 11 (6.9) 39 (15.6) 25 (27.8) 0.008 ˂ 0.001 0.011 ˂ 0.001
No 149 (93.1) 211 (84.4) 65 (72.2)
OR (95% CI)II vs. I = 2.50 (1.24–5.05), OR (95% CI)III vs. I = 5.21 (2.42–11.22), OR (95% CI)III vs. II = 2.08 (1.17–3.69)
Malignancy Yes 9 (5.6) 10 (4.0) 10 (11.1) 0.445 0.116 0.014 0.046
No 151 (94.4) 240 (96.0) 80 (88.9)
OR (95% CI)III vs. II = 3.00 (1.21–7.47)

Bold items indicate an statistically significant levels.

2.2. VDR gene polymorphisms genotyping by PCR-RFLP

Peripheral blood was taken from each of the participants and DNA extraction was applied by High Pure PCR Template Preparation Kit (Roche Applied Science, USA) following the manufacturer's recommendations. The concentration and purity, as well as quality of DNA, were determined by NanoDropND-1000 Spectrometer (ThermoScientific, Boston, MA) and gel electrophoresis, respectively. The target SNPs were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Primers were designed using PRIMER3 online software (version 4.1.0) (https://primer3.ut.ee/) and their specificity was assessed using primer blast and possible secondary structures were analyzed using GENE RUNNER software (Gene Runner version 6.5.52). The primer sequences, PCR thermal profiles, expected amplicon size, and RFLP patterns are summarized in Table 2 . It should be noted that in the present study, regardless of the type of substituted nucleotide(s) in SNP locations, the “capital” letter represents SNP-related major allele, and the small letter indicate minor allele. Accordingly, the major and minor alleles of ApaI [C and A (C > A), respectively] indicate as “A” and “a”, BsmI alleles indicate as “B” and “b”, Tru9I alleles indicate as “U” and “u”, TaqI alleles indicate as “T” and “t”, BglI alleles indicate as “G” and “g”, FokI alleles indicate as “F” and “f”, CDX2 alleles indicate as “C” and “c”, and EcoRV alleles indicate as “E” and “e”. It is expected that the restriction enzymes can digest PCR products of major alleles (capital letters) in SNPs ApaI, BsmI, BglI, CDX2, and EcoRV, and digest PCR products of minor alleles (small letters) in Tru9I, TaqI, and FokI. PCR reactions were carried out in a 25 μl reaction mixture containing 12.5 μl Taq DNA Polymerase 2× Master Mix (Amplicon, DENMARK), 1 μl of each primer (10 pmol), 1 μl genomic DNA (50 ng/μl), and 9.5 μl d.d.H2O in a thermal cycler instrument (Applied Biosystems, GeneAmp 2720, Singapore) under the PCR parameters indicated in Table 2. The PCR products were examined by 1.5% agarose gel electrophoresis to ensure appropriate amplification. Subsequently, the amplified PCR products were digested with the corresponding restriction enzymes including ApaI, BsmI, MseI (isoschizomer of Tru9I enzyme), TaqI, BglI, FokI, HpyCH4III (used to genotyping CDX2), and EcoRV following the manufacturer's instructions. Digested products were then electrophoresed on 2–3% agarose gel and the genotypes of all the SNPs were determined based on digestion patterns.

Table 2.

Primers sequences, PCR thermocycling profile, amplicon size, and RFLP pattern of different genotypes for the selected VDR gene polymorphisms.

SNP (RefSNPs)/other names restriction enzymes Primers sequences and PCR thermal profiles Amplicon (bp) Restriction fragments (bp)
rs7975232 ApaI Forward: 5′CTGCCGTTGAGTGTCTGTGT3′ 242 C: 191 + 51
Reverse: 5′TCGGCTAGCTTCTGGATCAT3′
Initial denaturation: 95 °C for 5 min, 35 cycles: 95 °C for 30 s, 58 °C for 30 s, and 72 °C for 30 s, and final extension: 72 °C for 7 min A: 242
rs1544410 BsmI Forward: 5′GGGAGACGTAGCAAAAGGAG3′ 297 G: 192 + 105
Reverse: 5′CCATCTCTCAGGCTCCAAAG3′
Initial denaturation: 95 °C for 5 min, 35 cycles: 95 °C for 30 s, 57 °C for 30 s, and 72 °C for 30 s, and final extension: 72 °C for 7 min A: 297
rs739837 BglI Forward: 5′CACCCAGCCCATTCTCTCTC3′ 248 C: 178+ 70
Reverse: 5′GCAGGTGTCTCTGTCCCTGA3′
Initial denaturation: 95 °C for 5 min, 35 cycles: 95 °C for 30 s, 62 °C for 30 s, and 72 °C for 30 s, and final extension: 72 °C for 7 min T: 248
rs731236 TaqI Forward: 5′CCCATGAAGCTTAGGAGGAA3′ 699 T: 699
Reverse: 5′TCATCTTGGCATAGAGCAGGT3′
Initial denaturation: 95 °C for 5 min, 35 cycles: 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 50 s, and final extension: 72 °C for 10 min C: 604 + 95
rs757343 Tru9I/MseI Forward: 5′CTTTGGAGCCTGAGAGATGG3′ 235 G: 235
Reverse: 5′CTCCAGTCCAGGAAAGCATC3′
Initial denaturation: 95 °C for 5 min, 35 cycles: 95 °C for 30 s, 59 °C for 30 s, and 72 °C for 30 s, and final extension: 72 °C for 7 min A: 162 + 73
rs2228570 FokI Forward: 5′CTGGCACTGACTCTGGCTCT3′ 247 C: 247
Reverse: 5′TGCTTCTTCTCCCTCCCTTT3′
Initial denaturation: 95 °C for 5 min, 35 cycles: 95 °C for 30 s, 62 °C for 30 s, and 72 °C for 30 s, and final extension: 72 °C for 7 min T: 185 + 62
rs11568820/CDX2 HpyCH4III Forward:: 5′AGGAGGGAGGGAGGAAGG3′ 414 G: 254 + 110 + 50
Reverse: 5′TGAGAGACATGAGCGTGGAG3′
Initial denaturation: 95 °C for 5 min, 35 cycles: 95 °C for 30 s, 61 °C for 30 s, and 72 °C for 30 s, and final extension: 72 °C for 7 min A: 254 + 160
rs4516035/GATA/A-1012G EcoRV Forward: 5′GAGGACAGGTGAAAAAGATGGGGTTC3′ 181 T: 154 + 27
Reverse: 5′CCTCCTCTGTAAGAGGCGAATAGCGAT3′
Initial denaturation: 95 °C for 5 min, 35 cycles: 95 °C for 30 s, 68 °C for 30 s, and 72 °C for 30 s, and final extension: 72 °C for 7 min C: 181

Bold items indicate an statistically significant levels.

2.3. Statistical analysis

All statistical analyses were implemented in the Statistical Package for the Social Sciences version 19 (IBM SPSS Inc., Chicago, IL, USA) and https://www.medcalc.org/calc/odds_ratio.php. The One-Sample Kolmogorov-Smirnov test was used to check the normal distribution of numerical variables. Student's unpaired t-tests and chi-square (χ2) tests were used to compare quantitative clinical data and qualitative demographic data between paired-groups of COVID-19, including asymptomatic vs mild and moderate (I vs. II), asymptomatic vs. severe/critical (I vs. III), and mild/moderate vs severe/critical groups (II vs. III). Odds ratios (ORs) and their associated 95% confidence intervals (95% CIs) were calculated by https://www.medcalc.org/calc/odds_ratio.php, as a measure to show the strength of associations with three groups of COVID-19, demographic data, and clinical outcomes. In all statistical tests, P-values <0.05 were considered to show statistically significant values.

3. Results

3.1. Baseline characteristics of patients

In our study, 500 COVID-19 patients were enrolled that were confirmed with a positive viral RT-PCR test, with an average age of 53.30 ± 16.16 years and 58.6% of them were men. The participants consisted of 32.0% asymptomatic patients (group I; average age 50.28 ± 16.76 years), 50.0% mild/moderate subjects (group II; average age 53.10 ± 16.10 years), and 18.0% severe/critical cases (group III; average age 59.19 ± 13.62 years). As presented in Table 1, no significant differences were found in sex ratio, defined as (No.of malesNo.of females), among three groups (P = 0.161), as well as between the paired-groups I vs II, I vs III, and II vs III (P = 0.988, P = 0.090, and P = 0.069, respectively). However, we observed significant differences in the average age of participants among three groups (P ˂ 0.001), and also in I than III and II vs. III, but not between groups I and II (I vs. II) (P ˂ 0.001, P = 0.006, and P = 0.187, respectively). Significant differences were observed between groups II and III in some features, including shortness of breath, fatigue, and parageusia (P values ˂ 0.001), but not in other variables, such as fever, sore throat, dry cough, headache, diarrhea, myalgia, nausea, and vomiting (P values >0.05).

In the case of comorbidities, we observed significant differences among three groups and also paired-groups of I-II, I-III, and II-III for diabetes, chronic renal disease, and asthma. According to these conditions, we found negative associations with the severity of COVID-19 patients. Higher remarkable frequencies of diabetes were observed in group II against group I, as well as in group III against groups I + II. Similar to diabetes, our data showed higher frequencies of chronic renal disease in group II than group I, as well as in group III than group I and also group II. Additionally, significantly higher frequencies of asthma conditions were observed in group III compared to group II. Interestingly, we found a higher frequency of asthma disease in group I versus group II, and the hypertension was noticeably higher in group III compared to group I and group II, but not in group pair I-II (P = 0.117). Additionally, a higher frequency of malignancy was shown in group III than group II, but not in paired-groups I-II and I-III (P = 0.445 and P = 0.116, respectively). We did not found any significant differences between/or among patients' groups for the cardiovascular disorder (P values >0.05).

3.2. VDR gene polymorphism genotype and allelic distribution in three various groups of COVID-19 patients

VDR gene polymorphisms were genotyped for all studied participants, and the resulted RFLP products were visualized by 2–3% agarose gel electrophoresis (Fig. 1 ). Distribution of genotypes with the respective allele frequencies and associations of the FokI, CDX2, and EcoRV or A-1012G/GATA, ApaI, BsmI, Tru9I, TaqI, BglI VDR polymorphisms were analyzed in COVID-19 patients consisting of three groups of asymptomatic (I), mild/moderate (II), severe/critical patients (III) (Table 3, Table 4 ).

Fig. 1.

Fig. 1

The PCR-RFLP patterns of eight selected VDR polymorphisms. (A) Genotypes were determined from lanes 1–12 for ApaI, BsmI, FokI, and TaqI polymorphisms; (B) Genotyping results for BgII, HpyCH4III, Tru9I/Msel, and EcorVI polymorphisms. The RFLP product sizes for each genotype of the selected SNPs are indicated in Table 2.

Table 3.

Allelic and genotypic comparison of selected polymorphisms in the 5′-end of VDR gene among three different groups of COVID-19 patients.

FokI (rs2228570)
Genotypes and alleles Group I (%) Group II (%) Group III (%)
FF (%) 75 (46.88) 96 (38.40) 30 (34.44)
Ff (%) 66 (41.25) 116 (46.40) 42 (33.33)
ff (%) 19 (11.87) 38(15.20) 18 (32.23)
F (%) 216 (67.50) 308 (61.60) 102 (56.67)
f (%) 104 (32.50) 192 (38.40) 78 (43.33)
HWE Chi-squared value (P- value) 0.57 (0.449) 0.09 (0.761) 0.22 (0.637)



Odds ratio (95% CI) and P- values
Genetic models Groups II & III vs. group I Group III vs. group I Group III vs. group II Group II vs. group I
Dominant FF + Ff vs. ff 0.68 (0.39–1.19), P = 0.181 0.54 (0.27–1.09), P = 0.086 0.72 (0.39–1.34), P = 0.294 0.75 (0.42–1.36), P = 0.344
ff vs. FF + Ff 1.47 (0.84–2.56), P = 0.181 1.85 (0.92–3.70), P = 0.086 1.39 (0.75–2.56), P = 0.294 1.33 (0.39–2.38), P = 0.344
Recessive ff + Ff vs. FF 1.50 (1.02–2.19), P = 0.037 1.77 (1.03–3.02), P = 0.038 1.25 (0.75–2.07), P = 0.394 1.42 (0.95–2.12), P = 0.090
FF vs. ff + Ff 0.67 (0.46–0.98), P = 0.037 0.57 (0.33–0.97), P = 0.038 0.80 (0.48–1.33), P = 0.394 0.70 (0.47–1.05), P = 0.090
Overdominant Ff vs. FF + ff 1.24 (0.85–1.81), P = 0.274 1.25 (0.74–2.10), P = 0.407 1.01 (0.62–1.64), P = 0.965 1.23 (0.83–1.84), P = 0.306
ff + FF vs. Ff 0.81 (0.55–1.18), P = 0.274 0.80 (0.85–1.82), P = 0.407 0.99 (0.61–1.61),P = 0.965 0.81 (0.54–1.21),P = 0.306
Codominant ff vs. FF 1.75 (0.97–3.18), P = 0.064 2.37 (1.10–5.12), P = 0.028 1.52 (0.76–3.04), P = 0.241 1.56 (0.83–2.93), P = 0.164
Ff vs. FF 1.42 (0.95–2.14), P = 0.087 1.59 (0.90–2.82), P = 0.113 1.16 (0.68–1.99), P = 0.594 1.37 (0.90–2.11), P = 0.146
Allelic F vs. f 0.73 (0.55–0.97), P = 0.028 0.63 (0.43–0.92), P = 0.016 0.82 (0.58–1.15), P = 0.246 0.77 (0.58–1.04), P = 0.087
f vs. F 1.37 (1.03–1.82), P = 0.028 1.59 (1.09–2.33), P = 0.016 1.22 (0.87–1.72), P = 0.246 1.30 (0.96–1.72), P = 0.087



CDX2 (rs11568820)
Genotypes and alleles Group I Group II Group III
CC (%) 73 (45.63) 95 (38.00) 28 (31.11)
Cc (%) 62 (38.75) 110 (44.00) 37 (41.11)
cc (%) 25 (15.62) 45 (18.00) 25 (27.78)
C (%) 208 (65.00) 300 (60.00) 93 (51.67)
c (%) 112 (35.00) 200 (40.00) 87 (48.33)
HWE Chi-squared value (P- value) 3.52 (0.061) 1.74 (0.188) 2.82 (0.093)



Odds ratio (95% CI) and P- values
Genetic models Groups II & III vs. group I Group III vs. group I Group III vs. group II Group II vs. group I
Dominant CC + Cc vs. cc 0.71 (0.43–1.18), P = 0.188 0.48 (0.26–0.90), P = 0.023 0.57 (0.33–1.00), P = 0.051 0.84 (0.49–1.44), P = 0.533
cc vs. CC + Cc 1.40 (0.85–2.33), P = 0.188 2.08 (1.11–3.85),P = 0.023 1.75 (1.00–3.03), P = 0.051 1.19 (0.69–2.04), P = 0.533
Recessive cc + Cc vs. CC 1.48 (1.01–2.17), P = 0.044 1.86 (1.08–3.20), P = 0.026 1.36 (0.81–2.27), P = 0.244 1.37 (0.92–2.05), P = 0.126
CC vs. cc + Cc 0.68 (0.46–0.99), P = 0.044 0.54 (0.31–0.93), P = 0.026 0.74 (0.44–1.24), P = 0.244 0.73 (0.49–1.09), P = 0.126
Overdominant Cc vs. CC + cc 1.20 (0.82–1.77), P = 0.343 1.10 (0.65–1.87), P = 0.714 0.89 (0.55–1.45), P = 0.635 1.24 (0.83–1.86), P = 0.294
CC + cc vs. Cc 0.83 (0.57–1.22), P = 0.343 0.91 (0.54–1.54), P = 0.714 1.12 (0.69–1.82), P = 0.635 0.81 (0.54–1.21), P = 0.294
Codominant cc vs. CC 1.67 (0.97–2.86), P = 0.066 2.63 (1.28–5.26), P = 0.008 1.89 (0.99–3.57), P = 0.054 1.39 (0.78–2.44), P = 0.270
Cc vs. CC 1.41 (0.93–2.13), P = 0.106 1.56 (0.86–2.83), P = 0.146 1.14 (0.65–2.00), P = 0.645 1.36 (0.88–2.11), P = 0.163
Allelic C vs. c 0.74 (0.56–0.97), P = 0.030 0.58 (0.40–0.84), P = 0.004 0.71 (0.51–1.00), P = 0.053 0.81 (0.60–1.08), P = 0.151
c vs. C 1.35 (1.03–1.79), P = 0.030 1.72 (1.19–2.50), P = 0.004 1.41 (1.00–1.96), P = 0.053 1.24 (0.93–1.67), P = 0.151



EcoRV (rs4516035)
Genotypes and alleles Group I Group II Group III
EE (%) 107 (66.88) 134 (53.60) 39 (43.33)
Ee (%) 43 (26.87) 95 (38.00) 46 (51.11)
ee (%) 10 (6.25) 21 (8.40) 5 (2.56)
E (%) 257 (80.31) 363 (72.60) 124 (68.89)
e (%) 63 (19.69) 137 (27.40) 56 (31.11)
HWE Chi-squared value (P- value) 3.61 (0.058) 0.50 (0.478) 3.332 (0.068)



Odds ratio (95% CI) and P- values
Genetic models Groups II & III vs. group I Group III vs. group I Group III vs. group II Group II vs. group I
Dominant EE + Ee vs. ee 0.81 (0.38–1.71), P = 0.574 1.13 (0.38–3.43), P = 0.823 1.56 (0.57–4.27), P = 0.387 0.73 (0.33–1.59), P = 0.423
ee vs. EE + Ee 1.24 (0.59–2.63), P = 0.574 0.89 (0.29–2.63), P = 0.823 0.64 (0.23–1.75), P = 0.387 1.37 (0.63–3.00), P = 0.423
Recessive ee + Ee vs. EE 1.95 (1.32–2.88), P ˂ 0.001 2.64 (1.55–4.49), P ˂ 0.001 1.51 (0.93–2.46), P = 0.096 1.75 (1.16–2.64), P = 0.008
EE vs. ee + Ee 0.51 (0.35–0.76), P ˂ 0.001 0.38 (0.22–0.65), P ˂ 0.001 0.66 (0.41–1.08), P = 0.096 0.57 (0.38–0.86), P = 0.008
Overdominant Ee vs. EE + ee 1.93 (1.28–2.91), P = 0.002 2.85 (1.66–4.89), P ˂ 0.001 1.71 (1.05–2.77), P = 0.031 1.67 (1.08–2.57), P = 0.021
EE + ee vs. Ee 0.52 (0.34–0.78), P = 0.002 0.35 (0.21–0.60), P ˂ 0.001 0.59 (0.36–0.95), P = 0.031 0.60 (0.39–0.93), P = 0.021
Codominant ee vs. EE 1.61 (0.75–3.47), P = 0.226 1.37 (0.44–4.27), P = 0.585 0.82 (0.29–2.31), P = 0.705 1.68 (0.76–3.71), P = 0.202
Ee vs. EE 2.03 (1.34–3.08), P ˂ 0.001 2.94 (1.69–5.11), P ˂ 0.001 1.66 (1.01–2.75), P = 0.047 1.76 (1.14–2.74), P = 0.012
Allelic E vs. e 0.62 (0.45–0.85), P = 0.004 0.54 (0.36–0.83), P = 0.004 0.84 (0.58–1.21), P = 0.344 0.65 (0.46–0.91), P = 0.013
e vs. E 1.61 (1.18–2.22), P = 0.004 1.85 (1.21–2.78), P = 0.004 1.19 (0.83–1.72), P = 0.344 1.54 (1.10–2.17), P = 0.013

Bold items indicate an statistically significant levels.

Table 4.

Allelic and genotypic comparison of 3′ end's VDR polymorphisms among three different groups of COVID-19 patients.

ApaI (rs7975232)
Genotypes and Alleles Group I (%) Group II (%) Group III (%)
AA (%) 51 (31.88) 107 (42.80) 31 (34.44)
Aa (%) 88 (55.00) 103 (41.20) 50 (55.56)
aa (%) 21 (13.12) 40 (16.00) 9 (10.00)
A (%) 190 (59.38) 317 (63.40) 112 (62.22)
a (%) 130 (40.62) 183 (36.60) 68 (37.78)
HWE Chi-squared value (P- value) 3.14 (0.076) 3.15 (0.076) 2.97 (0.085)



Odds ratio (95% CI) and P- values
Genetic models Groups II & III vs. group I Group III vs. group I Group III vs. group II Group II vs. group I
Dominant AA + Aa vs. aa 0.90 (0.52–1.56), P = 0.699 1.36 (0.59–3.11), P = 0.467 1.71 (0.80–3.69), P = 0.169 0.79 (0.45–1.40), P = 0.426
aa vs. AA + Aa 1.11 (0.64–1.92), P = 0.699 0.74 (0.32–1.70), P = 0.467 0.59 (0.27–1.25), P = 0.169 1.27 (0.71–2.22), P = 0.426
Recessive aa + Aa vs. AA 0.69 (0.46–1.02), P = 0.062 0.89 (0.52–1.54), P = 0.678 1.42 (0.86–2.35), P = 0.167 0.63 (0.41–0.95), P = 0.027
AA vs. aa + Aa 1.45 (0.98–2.17), P = 0.062 1.12 (0.65–1.92), P = 0.678 0.70 (0.43–1.16), P = 0.167 1.59 (1.05–2.44), P = 0.027
Overdominant Aa vs. AA + aa 0.67 (0.46–0.98), P = 0.037 1.02 (0.61–1.72), P = 0.932 1.78 (1.10–2.90), P = 0.020 0.57 (0.38–0.86), P = 0.007
AA + aa vs. Aa 1.49 (1.02–2.17), P = 0.037 0.98 (0.58–1.64), P = 0.932 0.56 (0.35–0.91), P = 0.020 1.75 (1.16–2.63), P = 0.007
Codominant aa vs. AA 0.86 (0.47–1.58), P = 0.631 0.71 (0.29–1.73), P = 0.446 0.78 (0.34–1.77), P = 0.549 0.91 (0.49–1.70), P = 0.762
Aa vs. AA 0.64 (0.42–0.97), P = 0.037 0.94 (0.53–1.65), P = 0.815 1.68 (0.99–2.83), P = 0.053 0.56 (0.36–0.87), P = 0.009
Allelic A vs. a 1.17 (0.89–1.54), P = 0.260 1.13 (0.78–1.64), P = 0.532 0.95 (0.67–1.35), P = 0.779 1.19 (0.89–1.58), P = 0.247
a vs. A 0.86 (0.65–1.12), P = 0.260 0.89 (0.61–1.28), P = 0.532 1.05 (0.74–1.49), P = 0.779 0.84 (0.63–1.12), P = 0.247



BsmI (rs1544410)
Genotypes and alleles Group I Group II Group III
BB (%) 63 (39.38) 112 (44.80) 29 (32.22)
Bb (%) 82 (51.25) 119 (47.60) 50 (55.56)
bb (%) 15 (9.37) 19 (7.60) 11 (12.22)
B (%) 208 (65.00) 343 (68.60) 108 (60.00)
b (%) 112 (35.00) 157 (31.40) 72 (40.00)
HWE Chi-squared value (P- value) 2.56 (0.110) 2.75 (0.097) 2.23 (0.135)



Odds ratio (95% CI) and P- values
Genetic models Groups II & III vs. group I Group III vs. group I Group III vs. group II Group II vs. group I
Dominant BB + Bb vs. bb 1.07 (0.56–2.05), P = 0.841 0.74 (0.33–1.70), P = 0.480 0.59 (0.27–1.30), P = 0.189 1.26 (0.62–2.55), P = 0.526
bb vs. BB + Bb 0.94 (0.49–1.79), P = 0.841 1.35 (0.59–3.00), P = 0.480 1.70 (0.77–3.70), P = 0.189 0.79 (0.39–1.61), P = 0.526
Recessive bb + Bb vs. BB 0.92 (0.63–1.35), P = 0.657 1.37 (0.79–2.35), P = 0.261 1.71 (1.03–2.84), P = 0.039 1.38 (0.94–2.04), P = 0.104
BB vs. bb + Bb 1.09 (0.74–1.59), P = 0.657 0.73 (0.43–1.27), P = 0.261 0.59 (0.35–0.97), P = 0.039 0.73 (0.49–1.06), P = 0.104
Overdominant Bb vs. BB + bb 0.94 (0.65–1.37), P = 0.747 1.19 (0.71–2.00), P = 0.513 2.43 (1.52–3.89), P ˂ 0.001 0.86 (0.58–1.29), P = 0.471
BB + bb vs. Bb 1.06 (0.73–1.54), P = 0.747 0.84 (0.50–1.41), P = 0.513 0.41 (0.26–0.66), P ˂ 0.001 1.16 (0.78–1.72), P = 0.471
Codominant bb vs. BB 0.89 (0.45–1.78), P = 0.748 1.59 (0.65–3.89), P = 0.307 2.24 (0.96–5.22), P = 0.063 0.71 (0.34–1.50), P = 0.372
Bb vs. BB 0.92 (0.62–1.37), P = 0.684 1.33 (0.75–2.33), P = 0.328 1.62 (0.96–2.74), P = 0.071 0.82 (0.54–1.24), P = 0.341
Allelic B vs. b 1.06 (0.80–1.40), P = 0.681 0.81 (0.55–1.18), P = 0.266 0.69 (0.48–0.98), P = 0.037 1.18 (0.87–1.58), P = 0.284
b vs. B 0.94 (0.71–1.25), P = 0.681 1.24 (0.85–1.82), P = 0.266 1.45 (1.02–2.08), P = 0.037 0.85 (0.63–1.15), P = 0.284



Tru9I (rs757343)
Genotypes and alleles Group I Group II Group III
UU (%) 119 (74.37) 199 (79.60) 63 (70.00)
Uu (%) 35 (21.88) 45 (18.00) 22 (24.44)
uu (%) 6 (3.75) 6 (2.40) 5 (5.56)
U (%) 273 (85.31) 443 (88.60) 148 (82.22)
u (%) 47 (14.69) 57 (11.40) 32 (17.78)
HWE Chi-squared value (P- value) 2.59 (0.108) 2.97 (0.085) 2.42 (0.120)



Odds ratio (95% CI) and P- values
Genetic models Groups II & III vs. group I Group III vs. group I Group III vs. group II Group II vs. group I
Dominant UU + Uu vs. uu 1.17 (0.42–3.21), P = 0.767 0.66 (0.20–2.24), P = 0.507 0.42 (0.12–1.41), P = 0.159 1.58 (0.50–5.00), P = 0.433
uu vs. UU + Uu 0.86 (0.31–2.38), P = 0.676 1.52 (0.45–5.00), P = 0.507 2.38 (0.71–8.33), P = 0.159 0.63 (0.20–2.00), P = 0.433
Recessive uu + Uu vs. UU 0.86 (0.56–1.37), P = 0.511 1.24 (0.70–2.21), P = 0.456 1.67 (0.97–2.89), P = 0.065 0.74 (0.47–1.19), P = 0.217
UU vs. uu + Uu 1.16 (0.73–1.79), P = 0.511 0.81 (0.45–1.43), P = 0.456 0.60 (0.35–1.03), P = 0.065 1.35 (0.84–1.13), P = 0.217
Overdominant Uu vs. UU + uu 0.88 (0.53–1.39), P = 0.575 1.16 (0.63–2.13), P = 0.642 1.47 (0.83–2.63), P = 0.189 0.78 (0.48–1.29), P = 0.335
UU + uu vs. Uu 1.14 (0.72–1.89), P = 0.575 0.86 (0.47–1.59), P = 0.642 0.68 (0.38–1.21), P = 0.189 1.28 (0.78–2.08), P = 0.335
Codominant uu vs. UU 0.83 (0.30–2.31), P = 0.725 1.57 (0.46–5.36), P = 0.468 2.63 (0.78–8.92), P = 0.120 0.60 (0.19–1.90), P = 0.383
Uu vs. UU 0.87 (0.55–1.38), P = 0.554 1.19 (0.64–2.20), P = 0.584 1.54 (0.86–2.77), P = 0.144 0.77 (0.47–1.26), P = 0.300
Allelic U vs. u 1.14 (0.78–1.67), P = 0.492 0.80 (0.49–1.30), P = 0.364 0.60 (0.37–0.95), P = 0.031 1.34 (0.88–2.03), P = 0.169
u vs. U 0.88 (0.60–1.28), P = 0.492 1.25 (0.77–2.04), P = 0.364 1.67 (1.05–2.70), P = 0.031 0.75 (0.49–1.14), P = 0.169



TaqI (rs731236)
Genotypes and alleles Group I Group II Group III
TT (%) 87 (54.38) 121 (48.40) 51 (56.67)
Tt (%) 56 (35.00) 96 (38.40) 29 (32.22)
tt (%) 17 (10.62) 33 (13.20) 10 (11.11)
T (%) 230 (71.88) 338 (67.60) 131 (72.78)
t (%) 90 (28.13) 162 (32.40) 49 (27.22)
HWE Chi-squared value (P- value) 2.89 (0.089) 3.81 (0.051) 3.14 (0.076)



Odds ratio (95% CI) and P- values
Genetic models Groups II & III vs. group I Group III vs. group I Group III vs. group II Group II vs. group I
Dominant TT + Tt vs. tt 0.82 (0.45–1.49), P = 0.517 0.95 (0.42–2.18), P = 0.905 1.22 (0.57–2.58), P = 0.610 0.78 (0.42–1.46), P = 0.438
tt vs. TT + Tt 1.22 (0.67–2.22), P = 0.517 1.05 (0.46–2.38), P = 0.905 0.82 (0.39–1.75), P = 0.610 1.28 (0.69–2.38), P = 0.438
Recessive tt + Tt vs. TT 1.16 (0.80–1.70), P = 0.429 0.91 (0.54–1.53), P = 0.727 0.72 (0.44–1.17), P = 0.179 1.27 (0.85–1.89), P = 0.238
TT vs. tt + Tt 0.86 (0.59–1.25), P = 0.429 1.10 (0.65–1.85), P = 0.727 1.39 (0.86–2.27), P = 0.179 0.79 (0.53–1.18), P = 0.238
Overdominant Tt vs. TT + tt 1.08 (0.73–1.60), P = 0.702 0.88 (0.51–1.53), P = 0.656 0.76 (0.46–1.27), P = 0.298 1.16 (0.77–1.75), P = 0.487
TT + tt vs. Tt 0.93 (0.63–1.37), P = 0.702 1.14 (0.65–1.96), P = 0.656 1.32 (0.79–21.17), P = 0.298 0.86 (0.57–1.30), P = 0.487
Codominant tt vs. TT 1.28 (0.69–2.37), P = 0.435 1.00 (0.43–2.36), P = 0.994 0.72 (0.33–1.57), P = 0.407 1.40 (0.73–2.67), P = 0.312
Tt vs. TT 1.13 (0.75–1.70), P = 0.559 0.883 (0.50–1.56), P = 0.668 0.72 (0.42–1.22), P = 0.217 1.23 (0.80–1.89), P = 0.340
Allelic T vs. t 0.87 (0.65–1.17), P = 0.351 1.05 (0.70–1.57), P = 0.829 1.28 (0.89–1.87), P = 0.199 0.82 (0.60–1.11), P = 0.196
t vs. T 1.15 (0.59–1.54), P = 0.351 0.95 (0.64–1.43), P = 0.829 0.78 (0.54–1.12), P = 0.199 1.22 (0.90–1.67), P = 0.196



BglI (rs739837)
Genotypes and alleles Group I Group II Group III
GG (%) 98 (61.25) 160 (64.00) 60 (66.67)
Gg (%) 56 (35.00) 74 (29.60) 24 (26.66)
gg (%) 6 (3.75) 16 (6.40) 6 (6.67)
G (%) 252 (78.75) 394 (78.80) 144 (80.00)
g (%) 68 (21.25) 106 (21.20) 36 (20.00)
HWE Chi-squared value (P- value) 0.34 (0.563) 3.25 (0.071) 2.50 (0.114)



Odds ratio (95% CI) and P- values
Genetic models Groups II & III vs. group I Group III vs. group I Group III vs. group II Group II vs. group I
Dominant GG + Gg vs. gg 0.56 (0.22–1.42), P = 0.223 0.55 (0.17–1.74), P = 0.307 0.96 (0.36–2.53), P = 0.930 0.57 (0.22–1.49), P = 0.251
gg vs. GG + Gg 1.79 (0.70–4.55), P = 0.223 1.82 (0.58–5.88), P = 0.307 1.04 (0.40–2.78), P = 0.930 1.75 (0.67–4.55), P = 0.251
Recessive gg + Gg vs. GG 0.86 (0.59–1.27), P = 0.454 0.79 (0.46–1.36), P = 0.394 0.89 (0.54–1.48), P = 0.650 0.89 (0.59–1.34), P = 0.574
GG vs. gg + Gg 1.16 (0.79–1.70), P = 0.454 1.27 (0.74–2.17), P = 0.394 1.12 (0.68–1.85), P = 0.650 1.12 (0.75–1.70), P = 0.574
Overdominant Gg vs. GG + gg 0.75 (0.51–1.12), P = 0.164 0.68 (0.38–1.19), P = 0.176 0.87 (0.50–1.49), P = 0.599 0.78 (0.51–1.19), P = 0.252
GG + gg vs. Gg 1.33 (0.89–1.96), P = 0.164 1.47 (0.84–2.63), P = 0.176 1.15 (0.67–2.00), P = 0.599 1.28 (0.84–1.96), P = 0.252
Codominant gg vs. GG 1.63 (0.64–4.16), P = 0.303 1.63 (0.50–5.30), P = 0.414 1.00 (0.37–2.68), P = 1.000 1.63 (0.62–4.32), P = 0.322
Gg vs. GG 0.78 (0.52–1.17), P = 0.229 0.70 (0.39–1.25), P = 0.225 0.87 (0.50–1.50), P = 0.603 0.81 (0.53–1.24), P = 0.334
Allelic G vs. g 1.02 (0.74–1.42), P = 0.894 1.08 (0.69–1.70), P = 0.741 1.08 (0.71–1.64), P = 0.734 1.00 (0.71–1.41), P = 0.986
g vs. AG 0.98 (0.70–1.35), P = 0.894 0.93 (0.59–1.45), P = 0.741 0.93 (0.61–1.41), P = 0.734 1.00 (0.71–1.41), P = 0.986

Bold items indicate an statistically significant levels.

As it is indicated in Table 3, significant differences were found between asymptomatic (I) and symptomatic (II + III) patients in the genotypic distribution of FokI SNP only in the recessive genetic model, in which wild-type allele (“F”) is recessive against to mutant allele (“f”). Based on this genetic model, a significantly lower genotypic frequency of “FF vs. ff + Ff” (P = 0.037) was observed in symptomatic compared to asymptomatic cases. Furthermore, genotypic distributions of the FokI showed a remarkable discrepancy in severe/critical patients compared to asymptomatic cases in recessive and codominant. No significant discrepancies were observed between asymptomatic and mild/moderate patients, as well as between mild/moderate and severe/critical patients for none of the proposed genetic models. Similar to genotypes, remarkable differences were found for FokI allelic distribution between symptomatic and asymptomatic, as well as between severe/critical and asymptomatic COVID-19 subjects. No remarkable discrepancies were found between asymptomatic and mild/moderate groups, as well as mild/moderate and severe/critical patients.

The genotypic distributions of the second selected 5′-end's VDR gene polymorphism, CDX2, in three various groups of COVID-19 patients were indicated in Table 3. The allelic frequency of CDX2 polymorphism, which is known as “C” (Wild-type) and “c” (mutated), was different in asymptomatic, mild/moderate, and severe/critical patients. We observed significant discrepancies in CDX2 genotypic distribution between symptomatic (II + III) and asymptomatic (I) groups only in the recessive genetic model. Moreover, significant differences were showed in the distribution of CDX2 genotypes in severe/critical compared to asymptomatic cases in the dominant model, in the recessive model, and in the codominant model, however, the genotypic distribution of CDX2 was not significantly different in the overdominant model. CDX2 allelic distributions in three various types of COVID-19 patients demonstrated results similar to FokI. The CDX2 allele frequency was found to be higher in symptomatic patients (II + III) than asymptomatic patients. Moreover, the allelic frequency of CDX2 was revealed to be significantly different in group III than group I. No significant discrepancies were identified in allelic and genotypic distribution of CDX2 SNP between mild/moderate vs. asymptomatic, as well as mild/moderate vs. severe/critical groups [P values >0.05].

EcoRV polymorphism was the last selected SNP located in the 5′-end of the VDR gene, which showed more complexity in allelic and genotypic distributions (Table 3). Significantly, EcoRV genotypes were differentially distributed between symptomatic group (II + III) and asymptomatic group in three genetic models, including recessive, overdominant, and codominant (“Ee vs. EE") genetic models (P < 0.05). Similarly, our results showed a significantly different EcoRV genotypic distribution in both severe/critical group and mild/moderate group against the asymptomatic group in recessive, overdominant, and codominant (“Ee vs. EE") models (P < 0.05). The EcoRV genotypic distribution showed significant deviation between severe/critical patients and mild/moderate patients in two genetic models, including overdominant and codominant (P < 0.05). Furthermore, our findings demonstrated the significant allelic distribution of the EcoRV SNP between whole paired groups, excluding in Group III vs. group II.

The first selected 3′-end VDR gene polymorphism to evaluate its association with COVID-19 patients' severity was ApaI. As it has been shown in Table 4, ApaI genotypic distributions were remarkably different between symptomatic group (II + III) and asymptomatic group in two genetic models, including overdominant and codominant (P < 0.05). Moreover, we observed significant differences in the distribution of ApaI genotypes in the severe/critical group than the mild/moderate group in the overdominant genetic model, as well as in the mild/moderate group compared to asymptomatic patients in recessive and overdominant genetic models. Amazingly, we did not find any significant discrepancies in ApaI genotypic distribution between severe/critical and asymptomatic groups in any of the proposed genetic models. Moreover, no significant differences were found in ApaI allelic distribution among three different types of COVID-19 (P > 0.05).

The genotypic distribution of BsmI, the second studied SNP located in the 3′-end's VDR gene, revealed remarkable discrepancies only in the severe/critical group compared to the mild/moderate group for two genetic models, including recessive and overdominant models, in which wild-type allele (B) is recessive against mutant allele (b) (Table 4). As presented in Table 4, BsmI genotypic distributions were not significantly different between other COVID-19 patients' groups, including groups II & III vs. group I, group III vs. group I, group II vs. group I (P > 0.05). We also didn't found remarkable discrepancies in BsmI allelic distribution between all paired groups, except between the severe/critical group and mild/moderate group (P < 0.05).

As it is shown in Table 4, the genotypic distributions of Tru9I, the third studied SNP located in the 3′ end's VDR gene, were not observed significantly different for any proposed genetic models, between three groups of COVID-19 patients, including symptomatic (II + III) and asymptomatic groups, severe/critical and asymptomatic groups, mild/moderate and asymptomatic groups, and eventually, severe/critical and mild/moderate groups (P > 0.05). Moreover, no significant discrepancies were found in Tru9I allelic distribution between paired groups, excluding in severe/critical group compared to mild/moderate group, in which lower rates of “U” vs. “u” and higher rates of “u” vs. “U” were significantly different between groups. TaqI polymorphism was another selected SNP in the present study that is located in the 3′ end's VDR gene. As is indicated in Table 4, our data didn't reveal any remarkable discrepancies in genotypic and allelic distributions of TaqI and BglI SNPs, for any recommended genetic models, between various groups of COVID-19 patients (P > 0.05).

3.3. Association of VDR gene polymorphisms with demographic and clinical features, and comorbidities of COVID-19 patients

We evaluate the potential association of selected VDR SNPs with various demographic and clinical features of patients, including gender, fever, sore throat, dry cough, headache, shortness of breath, diarrhea, myalgia, fatigue, nausea, vomiting, and parageusia (Table 5, Table 6 ). Additionally, the association of VDR gene polymorphisms with multifactorial diseases that are revealed to function as critical prognostic comorbidities including hypertension, diabetes, asthma, cardiovascular disease, chronic renal disease, and malignancy, were measured in three groups of COVID-19 patients (Table 5, Table 6). Our results didn't show any significant associations between studied VDR gene SNPs and the aforementioned demographic/clinical features as well as comorbidities in both asymptomatic and in the mild/moderate COVID-19 patients (P values >0.05). However, regarding the comorbidities, we found significant associations of EcoRV and BsmI SNPs with diabetes and chronic renal disease, respectively (P ˂ 0.001 and P = 0.010, respectively). However, no significant associations were observed between VDR polymorphisms and other comorbidities in mild/moderate patients (P values >0.05).

Table 5.

Association of 5′ end's VDR polymorphisms- related genotypes with different clinical data in COVID-19 patients.

Variables Status FokI
CDX2
EcoRV
FF Ff ff P CC Cc cc P EE Ee ee P
Asymptomatic patients (group I)
Gender Male 48 (53.3) 30 (33.3) 12 (13.3) 0.070 41 (45.6) 38 (42.2) 11 (12.2) 0.339 61 (67.8) 24 (26.7) 5 (5.6) 0.911
Female 27 (38.6) 36 (51.4) 7 (1.0) 32 (45.7) 24 (34.3) 14 (20.0) 46 (65.7) 19 (27.1) 5 (7.1)
Hypertension Yes 9(47.4) 9 (47.4) 1 (5.3) 0.609 9 (47.4) 8 (42.1) 2 (10.5) 0.804 12 (63.2) 4 (21.4) 3 (15.8) 0.178
No 66 (46.8) 57 (4.4) 18 (12.8) 64 (45.4) 54 (38.3) 23 (16.3) 95 (67.4) 39 (27.7) 7 (5.0)
Diabetes Yes 6(37.5) 6 (37.5) 4 (25.0) 0.226 5 (31.2) 8 (50.0) 3 (18.8) 0.473 13 (81.2) 2 (12.5) 1 (6.2) 0.384
No 69 (47.9) 60 (41.7) 15 (10.4) 68 (47.2) 54 (37.5) 22 (15.3) 94 (65.3) 41 (28.5) 9 (6.2)
Asthma Yes 8(36.4) 10 (45.5) 4 (18.2) 0.457 9 (40.9) 10 (45.5) 3 (13.6) 0.785 13 (59.1) 9 (40.9) 0 (0.0) 0.158
No 67 (48.6) 56 (40.6) 15 (10.9) 64 (46.4) 52 (37.7) 22 (15.9) 94 (68.1) 34 (24.6) 10 (7.2)
Cardiovascular disease Yes 6(33.3) 10 (55.6) 2 (11.1) 0.405 8 (44.4) 7 (38.9) 3 (16.7) 0.990 9 (50.0) 7 (38.9) 2 (11.1) 0.257
No 69 (48.6) 56 (39.4) 17 (12.0) 65 (45.8) 55 (38.7) 22 (15.5) 98 (69.0) 36 (25.4) 8 (5.6)
Chronic renal disease Yes 3 (27.3) 7 (63.6) 1 (9.1) 0.289 5 (45.5) 5 (45.5) 1 (9.1) 0.795 10 (90.9) 1 (9.1) 0 (0.0) 0.207
No 72 (48.3) 59 (39.6) 18 (12.1) 68 (54.6) 57 (38.3) 24 (16.1) 97 (65.1) 42 (28.2) 10 (6.7)
Malignancy Yes 3 (33.3) 5 (55.6) 1 (11.1) 0.653 2 (22.2) 4 (44.4) 3 (33.3) 0.208 7 (77.8) 2 (22.2) 0 (0.0) 0.656
No 72 (47.7) 61 (40.4) 18 (11.9) 71 (47.0) 58 (38.4) 22 (14.6) 100 (66.2) 41 (27.2) 10 (6.6)



Mild/moderate patients (group II)
Gender Male 52 (36.6) 72 (50.7) 18 (12.7) 0.227 52 (36.6) 61 (43.0) 29 (20.4) 0.517 70 (49.3) 56 (39.4) 16 (11.3) 0.104
Female 44 (40.7) 44 (40.7) 20 (18.5) 43 (39.8) 49 (45.4) 16 (14.8) 64 (59.3) 39 (36.1) 5 (4.6)
Fever Yes 50 (35.5) 65 (46.1) 26 (18.4) 0.227 58 (41.1) 58 (41.1) 25 (17.7) 0.484 77 (54.6) 54 (38.3) 10 (7.1) 0.695
No 46 (42.2) 51 (46.8) 12 (11.0) 37 (33.9) 52 (47.7) 20 (18.3) 57 (52.3) 41 (37.6) 11 (10.1)
Sore throat Yes 31 (37.8) 37 (45.1) 14 (17.1) 0.845 28 (34.1) 40 (48.8) 14 (17.1) 0.557 43 (52.4) 34 (41.5) 5 (6.1) 0.553
No 65 (38.7) 79 (47.0) 24 (14.3) 67 (39.9) 70 (41.7) 31 (18.5) 91 (54.2) 61 (36.3) 16 (9.5)
Dry cough Yes 56 (38.9) 69 (47.9) 19 (13.2) 0.580 61 (42.4) 59 (41.0) 24 (16.7) 0.254 79 (54.9) 52 (36.1) 13 (9.0) 0.749
No 40 (37.7) 47 (44.3) 19 (17.9) 34 (32.1) 51 (48.1) 21 (19.8) 55 (51.9) 43 (40.6) 8 (7.5)
Headache Yes 19 (38.8) 24 (49.0) 6 (12.2) 0.803 17 (34.7) 21 (42.9) 11 (22.4) 0.649 51 (42.9) 23 (46.9) 5 (10.2) 0.243
No 77 (38.3) 92 (45.8) 32 (15.9) 78 (38.8) 89 (44.3) 34 (16.9) 113 (56.2) 72 (35.8) 16 (8.0)
Shortness of breath Yes 15 (46.9) 10 (31.2) 7 (21.9) 0.167 10 (31.2) 14 (43.8) 8 (25.0) 0.487 15 (46.9) 13 (40.6) 4 (12.5) 0.574
No 81 (37.2) 106 (48.6) 31 (14.2) 85 (39.0) 96 (44.0) 37 (17.0) 119 (54.6) 82 (37.6) 17 (7.8)
Diarrhea Yes 6 (31.6) 10 (52.6) 3 (15.8) 0.808 5 (26.3) 11 (57.9) 3 (15.8) 0.428 14 (73.7) 4 (21.1) 1 (5.3) 0.188
No 90 (39.0) 106 (45.9) 35 (15.2) 90 (39.0) 99 (42.9) 42 (18.2) 120 (51.9) 91 (31.4) 20 (8.7)
Myalgia Yes 21 (33.9) 32 (51.6) 9 (14.5) 0.622 27 (43.5) 24 (38.7) 11 (17.7) 0.550 39 (62.9) 20 (32.3) 3 (4.8) 0.193
No 75 (39.9) 84 (44.7) 29 (15.4) 68 (36.2) 86 (45.7) 34 (18.1) 95 (50.5) 75 (39.9) 18 (9.6)
Fatigue Yes 8 (30.8) 13 (50.0) 5 (19.2) 0.660 11 (42.3) 11 (42.3) 4 (15.4) 0.873 12 (46.2) 12 (46.2) 2 (7.7) 0.662
No 88 (39.3) 103 (46.0) 33 (14.7) 84 (37.5) 99 (44.2) 41 (18.3) 122 (54.5) 83 (37.1) 19 (8.5)
Nausea Yes 10 (41.7) 10 (41.7) 4 (16.7) 0.887 7 (29.2) 14 (58.3) 3 (12.5) 0.328 15 (62.5) 6 (25.0) 3 (12.5) 0.349
No 86 (38.1) 116 (46.9) 34 (15.0) 88 (38.9) 96 (42.5) 42 (18.6) 119 (52.7) 89 (39.4) 18 (8.0)
Vomiting Yes 7 (38.9) 9 (50.5) 2 (11.1) 0.847 9 (50.0) 5 (27.8) 4 (22.2) 0.352 9 (50.0) 7 (38.9) 2 (11.1) 0.896
No 89 (38.4) 107 (46.1) 36 (15.5) 86 (37.1) 105 (45.3) 41 (17.7) 125 (53.9) 88 (37.9) 19 (8.2)
Parageusia Yes 5 (41.7) 6 (50.0) 1 (8.3) 0.794 5 (41.7) 4 (33.3) 3 (25.0) 0.700 8 (66.7) 3 (25.0) 1 (8.3) 0.618
No 91 (38.2) 110 (46.2) 37 (15.5) 90 (37.8) 106 (44.5) 42 (17.6)0.700 126 (52.9) 92 (38.7) 20 (8.4)
Hypertension Yes 13 (29.5) 23 (52.3) 8 (18.2) 0.407 12 (27.3) 20 (45.5) 12 (27.3) 0.123 26 (59.1) 14 (31.8) 4 (9.1) 0.648
No 83 (40.3) 93 (45.1) 30 (14.6) 83 (40.3) 90 (43.7) 33 (16.0) 108 (52.4) 81 (39.3) 17 (8.3)
Diabetes Yes 14 (31.8) 23 (52.3) 7 (15.9) 0.601 12 (27.3) 22 (50.0) 10 (22.7) 0.257 11 (25.0) 23 (52.3) 10 (22.7) ˂ 0.001
No 82 (39.8) 93 (45.1) 31 (15.0) 83 (40.3) 88 (42.7) 35 (17.0) 123 (59.7) 72 (35.0) 11 (5.3)
Asthma Yes 3 (21.4) 8 (57.1) 3 (21.4) 0.395 6 (42.9) 7 (50.0) 1 (7.1) 0.553 6 (42.9) 6 (42.9) 2 (14.3) 0.600
No 93 (39.4) 108 (45.8) 35 (14.8) 89 (37.7) 103 (43.6) 44 (18.6) 128 (54.2) 89 (37.7) 19 (8.1)
Cardiovascular disease Yes 12 (50.0) 7 (29.2) 5 (20.8) 0.204 9 (37.5) 11 (45.8) 4 (16.7) 0.976 12 (50.0) 9 (37.5) 3 (12.5) 0.742
No 84 (37.2) 109 (48.2) 33 (14.6) 86 (38.1) 99 (43.8) 41 (18.1) 122 (54.0) 86 (38.1) 18 (8.0)
Chronic renal disease Yes 18 (46.2) 15 (38.5) 6 (15.4) 0.509 14 (35.9) 19 (48.7) 6 (15.4) 0.793 20 (51.3) 17 (43.6) 2 (5.1) 0.602
No 78 (37.0) 101 (47.9) 32 (15.2) 81 (38.4) 91 (43.1) 39 (18.5) 114 (54.0) 78 (37.0) 19 (9.0)
Malignancy Yes 4 (40.0) 5 (50.0) 1 (10.0) 0.895 5 (50.0) 5 (50.0) 0 (0.0) 0.308 7 (70.0) 1 (10.0) 2 (20.0) 0.114
No 92 (38.3) 111 (46.2) 37 (15.4) 90 (37.5) 105 (43.8) 45 (18.8) 127 (52.9) 94 (39.2) 19 (7.9)



Severe and critical patients (group III)
Gender Male 19 (31.1) 27 (44.3) 15 (24.6) 0.286 16 (26.2) 25 (41.0) 20 (32.8) 0.206 26 (42.6) 31 (50.8) 4 (6.6) 0.832
Female 11 (37.9) 15 (51.7) 3 (10.3) 12 (41.4) 12 (41.4) 5 (17.2) 13 (44.8) 15 (51.7) 1 (3.4)
Fever Yes 16 (30.8) 22 (42.3) 14 (26.9) 0.158 18 (34.6) 23 (44.2) 11 (21.2) 0.256 23 (44.2) 25 (48.1) 4 (7.7) 0.533
No 14 (36.8) 20 (52.6) 4 (10.5) 10 (26.3) 14 (36.8) 14 (36.8) 16 (42.1) 21 (55.3) 1 (2.6)
Sore throat Yes 6 (23.1) 11 (42.3) 9 (34.6) 0.074 6 (23.1) 11 (42.3) 9 (34.6) 0.500 12 (46.2) 12 (46.2) 2 (7.7) 0.762
No 24 (37.5) 31 (48.4) 9 (14.1) 22 (34.4) 26 (40.6) 16 (25.0) 27 (42.2) 34 (53.1) 3 (4.7)
Dry cough Yes 10 (22.7) 22 (50.0) 12 (27.3) 0.068 15 (34.1) 16 (36.4) 13 (29.5) 0.665 22 (50.0) 19 (43.2) 3 (6.8) 0.335
No 20 (43.5) 20 (43.5) 6 (13.0) 13 (28.3) 21 (45.7) 12 (26.1) 17 (37.0) 27 (58.7) 2 (4.3)
Headache Yes 2 (20.0) 6 (60.0) 2 (20.0) 0.598 3 (30.0) 5 (50.0) 2 (20.0) 0.792 5 (50.0) 3 (30.0) 2 (20.0) 0.070
No 28 (35.0) 36 (45.0) 16 (20.0) 25 (31.2) 32 (40.0) 23 (28.7) 34 (42.5) 43 (53.8) 3 (3.8)
Shortness of breath Yes 19 (32.2) 27 (45.8) 13 (22.0) 0.799 22 (37.3) 26 (44.1) 11 (18.6) 0.022 29 (49.2) 26 (44.1) 4 (6.8) 0.177
No 11 (35.5) 15 (48.4) 5 (16.1) 6 (19.4) 11 (35.5) 14 (45.2) 10 (32.3) 20 (64.5) 1 (3.2)
Diarrhea Yes 3 (27.3) 5 (45.5) 3 (27.3) 0.789 4 (36.4) 3 (27.3) 4 (36.4) 0.598 4 (36.4) 6 (54.5) 1 (9.1) 0.798
No 27 (34.2) 37 (46.8) 15 (19.0) 24 (30.4) 34 (43.0) 21 (26.6) 35 (44.3) 40 (50.6) 4 (5.1)
Myalgia Yes 5 (29.4) 8 (47.1) 4 (23.5) 0.892 4 (23.5) 9 (52.9) 4 (23.5) 0.539 6 (35.3) 9 (52.9) 2 (11.8) 0.410
No 25 (34.2) 34 (46.6) 14 (19.2) 24 (32.9) 28 (38.4) 21 (27.8) 33 (45.2) 37 (50.7) 3 (4.1)
Fatigue Yes 12 (38.7) 13 (41.9) 6 (19.4) 0.724 12 (38.7) 12 (38.7) 7 (22.6) 0.496 16 (51.6) 14 (45.2) 1 (3.2) 0.464
No 18 (30.5) 29 (49.2) 12 (20.3) 16 (27.1) 25 (42.4) 18 (30.5) 23 (39.) 32 (54.2) 4 (6.8)
Nausea Yes 4 (26.7) 8 (53.3) 3 (20.0) 0.814 5 (33.3) 3 (20.0) 7 (46.7) 0.117 4 (26.7) 10 (66.7) 1 (6.7) 0.360
No 26 (34.7) 34 (45.3) 15 (20.0) 23 (30.7) 34 (45.3) 18 (24.0) 35 (46.7) 36 (48.0) 4 (5.3)
Vomiting Yes 2 (18.2) 7 (63.6) 2 (18.2) 0.437 0 (0.0) 6 (54.5) 5 (45.5) 0.053 4 (36.4) 6 (54.5) 1 (9.1) 0.798
No 28 (35.4) 35 (44.3) 16 (20.3) 28 (35.4) 31 (39.2) 20 (25.3) 35 (44.3) 40 (50.6) 4 (5.1)
Parageusia Yes 12 (46.2) 11 (42.3) 3 (11.5) 0.196 8 (30.8) 11 (42.3) 7 (26.9) 0.988 10 (38.5) 15 (57.7) 1 (3.8) 0.704
No 18 (21.8) 31 (48.4) 15 (23.4) 20 (31.2) 26 (40.6) 18 (28.1) 29 (45.3) 31 (48.4) 4 (6.2)
Hypertension Yes 14 (31.1) 17 (37.8) 14 (31.1) 0.027 15 (33.3) 13 (28.9) 17 (37.8) 0.036 15 (33.3) 27 (60.0) 3 (6.7) 0.160
No 16 (35.6) 25 (55.6) 4 (8.9) 13 (28.9) 24 (53.3) 8 (17.8) 24 (53.3) 19 (42.2) 2 (4.4)
Diabetes Yes 12 (37.5) 12 (37.5) 8 (25.0) 0.412 8 (25.0) 10 (31.2) 14 (43.8) 0.042 9 (28.1) 22 (68.8) 1 (3.1) 0.045
No 18 (31.0) 30 (51.7) 10 (17.2) 20 (34.5) 27 (46.6) 11 (19.0) 30 (51.7) 24 (41.4) 4 (6.9)
Asthma Yes 7 ()46.7 5 (33.3) 3 (20.0) 0.439 4 (26.7) 8 (53.3) 3 (20.0) 0.560 8 (53.3) 6 (40.0) 1 (6.7) 0.641
No 23 (30.7) 37 (49.3) 15 (20.0) 24 (32.0) 29 (38.7) 22 (29.3) 31 (41.3) 40 (53.3) 4 (5.3)
Cardiovascular disease Yes 4 (36.4) 3 (27.3) 4 (36.4) 0.256 6 (54.5) 4 (36.4) 1 (9.1) 0.145 6 (54.5) 5 (45.5) 0 (0.0) 0.566
No 26 (32.9) 39 (49.4) 14 (17.7) 22 (27.8) 33 (41.8) 24 (30.4) 33 (41.8) 41 (51.9) 5 (6.3)
Chronic renal disease Yes 8 (32.0) 10 (40.0) 17 (28.0) 0.483 10 (40.0) 10 (40.0) 5 (20.0) 0.440 10 (40.0) 15 (60.0) 0 (0.0) 0.280
No 22 (33.8) 32 (49.2) 11 (16.9) 18 (27.7) 27 (41.5) 20 (30.8) 29 (44.6) 31 (47.7) 5 (7.7)
Malignancy Yes 2 (20.0) 5 (50.0) 3 (30.0) 0.552 3 (30.0) 5 (50.0) 2 (20.0) 0.792 4 (40.0) 5 (50.0) 1 (10.0) 0.675
No 28 (35.0) 37 (46.2) 15 (18.8) 25 (31.2) 32 (40.0) 23 (28.7) 34 (42.5) 42 (52.5) 4 (5.0)

Bold items indicate an statistically significant levels.

Table 6.

Association of 3′ end's VDR polymorphisms- related genotypes with different clinical data in COVID-19 patients.

Variables Status ApaI
BsmI
Tru9I
TaqI
BglI
AA Aa aa P BB Bb bb P UU Uu uu P TT Tt tt P GG Gg gg P
Asymptomatic patients (group I)
Gender Male 29 (32.2) 47 (52.2) 14 (15.6) 0.543 34 (37.8) 44 (48.9) 12 (13.3) 0.150 70 (77.8) 17 (18.9) 3 (3.3) 0.534 46 (51.1) 36 (40.0) 8 (8.9) 0.293 52 (57.8) 33 (36.7) 5 (5.6) 0.308
Female 22 (31.4) 41 (58.6) 7 (10.0) 29 (41.4) 38 (54.3) 3 (4.3) 49 (70.0) 18 (21.9) 3 (4.3) 41 (58.6) 20 (28.6) 9 (12.9) 46 (65.7) 23 (32.9) 1 (1.4)
Hypertension Yes 4 (21.1) 13 (68.4) 2 (10.5) 0.447 11 (57.9) 7 (36.8) 1 (5.3) 0.208 16 (84.2) 3 (15.8) 0 (0.0) 0.483 11 (57.9) 6 (31.6) 2 (10.5) 0.941 13 (68.4) 5 (26.3) 1 (5.3) 0.678
No 47 (33.3) 75 (53.2) 19 (13.5) 52 (36.9) 75 (53.2) 14 (9.9) 103 (73.0) 32 (22.7) 6 (4.3) 76 (53.9) 50 (35.5) 15 (10.6) 85 (60.3) 51 (36.2) 5 (3.5)
Diabetes Yes 5 (31.2) 8 (50.0) 3 (18.8) 0.774 8 (50.0) 7 (43.8) 1 (6.2) 0.641 13 (81.2) 3 (18.8) 0 (0.0) 0.651 6 (37.5) 9 (56.2) 1 (6.2) 0.170 8 (50.0) 8 (50.0) 0 (0.0) 0.337
No 46 (31.9) 80 (55.6) 18 (12.5) 55 (38.2) 75 (52.1) 14 (9.7) 106 (73.6) 32 (22.2) 6 (4.2) 81 (56.2) 47 (32.6) 16 (11.1) 90 (62.5) 48 (33.3) 6 (4.2)
Asthma Yes 8 (36.4) 10 (45.5) 4 (18.2) 0.583 11 (50.0) 9 (40.9) 2 (9.1) 0.531 16 (72.7) 5 (22.7) 1 (4.5) 0.970 13 (59.1) 8 (36.4) 1 (4.5) 0.605 13 (59.1) 8 (36.4) 1 (4.5) 0.963
No 43 (31.2) 78 (56.5) 17 (12.3) 52 (37.7) 73 (52.9) 13 (9.4) 103 (74.6) 30 (21.7) 5 (3.6) 74 (3.6) 48 (34.8) 16 (11.6) 85 (61.6) 48 (34.8) 5 (3.6)
Cardiovascular disease Yes 5 (27.8) 10 (55.6) 3 (16.7) 0.860 9 (50.0) 7 (38.9) 2 (11.1) 0.535 15 (83.3) 3 (16.7) 0 (0.0) 0.540 11 (61.1) 5 (27.8) 2 (11.1) 0.788 13 (72.2) 4 (22.2) 1 (5.6) 0.467
No 46 (32.4) 78 (54.9) 18 (12.7) 54 (38.0) 75 (52.8) 13 (9.2) 104 (73.2) 32 (22.5) 6 (4.2) 76 (53.5) 51 (35.9) 15 (10.6) 85 (59.9) 52 (36.6) 5 (3.5)
Chronic renal disease Yes 3 (27.3) 7 (63.6) 1 (9.1) 0.825 5 (45.5) 6 (54.5) 0 (0.0) 0.537 8 (72.7) 3 (27.3) 0 (0.0) 0.739 6 (54.5) 4 (36.4) 1 (9.1) 0.984 6 (54.5) 5 (45.5) 0 (0.0) 0.638
No 48 (32.2) 81 (54.4) 20 (13.4) 58 (38.9) 76 (51.0) 15 (10.1) 111 (74.5) 32 (21.5) 6 (4.0) 81 (54.5) 52 (34.9) 16 (10.7) 92 (61.7) 51 (34.2) 6 (4.0)
Malignancy Yes 4 (44.4) 3 (33.3) 2 (2.22) 0.389 6 (66.7) 3 (33.3) 0 (0.0) 0.193 5 (55.6) 4 (44.4) 0 (0.0) 0.220 4 (44.4) 4 (44.4) 1 (11.1) 0.811 5 (55.6) 4 (44.4) 0 (0.0) 0.722
No 47 (31.1) 85 (56.3) 19 (12.6) 57 (37.7) 79 (52.3) 15 (9.9) 114 (75.5) 31 (20.5) 6 (4.0) 83 (55.0) 52 (34.4) 16 (10.6) 93 (61.6) 52 (34.4) 6 (4.0)



Mild/moderate patients (group II)
Gender Male 60 (42.3) 59 (41.5) 23 (16.2) 0.980 63 (44.4) 68 (47.9) 11 (7.7) 0.986 112 (78.9) 26 (18.3) 4 (2.8) 0.870 71 (50.0) 49 (34.5) 22 (15.5) 0.249 96 (67.6) 39 (27.5) 7 (4.9) 0.319
Female 47 (43.5) 44 (40.7) 17 (15.7) 49 (45.4) 51 (47.2) 8 (7.4) 87 (80.6) 19 (17.6) 2 (1.9) 50 (46.3) 47 (43.5) 11 (10.2) 64 (59.3) 35 (32.4) 9 (8.3)
Fever Yes 59 (41.8) 60 (42.6) 22 (15.6) 0.885 60 (42.6) 70 (49.6) 11 (7.8) 0.717 108 (76.6) 29 (20.6) 4 (2.8) 0.405 61 (43.3) 62 (44.0) 18 (12.8) 0.109 82 (58.2) 50 (35.5) 9 (6.4) 0.065
No 48 (44.0) 43 (39.4) 18 (16.5) 52 (47.7) 49 (45.0) 8 (7.3) 91 (83.5) 16 (14.7) 2 (1.8) 60 (55.0) 34 (31.2) 15 (13.8) 78 (71.6) 24 (22.0) 7 (6.4)
Sore throat Yes 39 (47.6) 31 (37.8) 12 (14.6) 0.568 34 (41.5) 42 (51.2) 6 (7.3) 0.722 71 (86.6) 9 (11.0) 2 (2.4) 0.129 37 (41.5) 32 (39.0) 13 (15.9) 0.627 52 (63.4) 24 (29.3) 6 (7.3) 0.918
No 68 (40.5) 72 (42.9) 28 (16.7) 78 (46.4) 77 (45.8) 13 (7.7) 128 (76.2) 36 (21.4) 4 (2.4) 84 (50.0) 64 (38.1) 20 (11.9) 108 (64.3) 50 (29.8) 10 (6.0)
Dry cough Yes 62 (43.1) 59 (41.0) 23 (16.0) 0.995 64 (44.4) 70 (48.6) 10 (6.9) 0.872 111 (77.1) 30 (208) 3 (2.1) 0.382 72 (50.0) 50 (34.7) 22 (15.3) 0.288 92 (63.9) 43 (29.9) 9 (6.2) 0.990
No 45 (42.5) 44 (41.5) 17 (16.0) 48 (45.3) 49 (46.2) 9 (8.5) 88 (83.0) 15 (14.2) 3 (2.8) 49 (46.2) 46 (43.4) 11 (10.4) 68 (64.2) 31 (29.2) 7 (6.6)
Headache Yes 23 (46.9) 17 (34.7) 9 (18.4) 0.582 21 (42.9) 24 (49.0) 4 (8.2) 0.951 40 (81.6) 7 (14.3) 2 (4.1) 0.544 26 (53.1) 18 (36.7) 5 (10.2) 0.694 34 (69.4) 13 (26.5) 2 (4.1) 0.612
No 84 (41.8) 86 (42.8) 31 (15.4) 91 (45.3) 95 (47.3) 15 (7.5) 159 (79.1) 38 (18.9) 4 (2.0) 95 (47.3) 78 (38.8) 28 (13.9) 126 (62.7) 61 (30.3) 14 (7.0)
Shortness of breath Yes 14 (43.8) 13 (40.6) 5 (15.6) 0.993 17 (53.1) 12 (37.5) 3 (9.4) 0.471 27 (84.4) 5 (15.6) 0 (0.0) 0.577 15 (46.9) 12 (37.5) 6 (15.6) 0.910 23 (71.9) 7 (21.9) 2 (6.2) 0.578
No 93 (42.7) 90 (41.3) 35 (16.1) 95 (43.6) 107 (49.1) 16 (7.3) 172 (78.9) 40 (18.3) 6 (2.8) 106 (48.6) 84 (38.5) 28 (12.8) 137 (62.8) 67 (30.7) 14 (6.4)
Diarrhea Yes 9 (47.4) 7 (36.8) 3 (15.8) 0.907 10 (52.6) 8 (42.1) 1 (5.3) 0.756 15 (78.9) 4 (21.1) 0 (0.0) 0.740 9 (47.4) 6 (31.6) 4 (21.1) 0.545 15 (78.9) 4 (21.1) 0 (0.0) 0.281
No 98 (42.4) 96 (41.6) 37 (16.0) 102 (44.2) 111 (48.1) 18 (7.8) 184 (79.7) 41 (17.7) 6 (2.6) 112 (48.5) 90 (39.0) 29 (12.6) 145 (62.8) 70 (30.3) 16 (6.9)
Myalgia Yes 26 (41.9) 30 (48.4) 6 (9.7) 0.211 26 (41.9) 31 (50.0) 5 (8.1) 0.872 48 (77.4) 14 (22.6) 0 (0.0) 0.224 29 (46.8) 27 (43.5) 6 (9.7) 0.499 45 72.6() 12 (19.4) 5 (8.1) 0.121
No 81 (43.1) 73 (38.8) 34 (18.1) 86 (45.7) 88 (46.8) 14 (7.4) 151 (80.3) 31 (16.5) 6 (3.2) 92 (48.9) 69 (36.7) 27 (14.4) 115 (61.2) 62 (33.0) 11 (5.9)
Fatigue Yes 11 (42.3) 12 (46.2) 3 (11.5) 0.765 11 (42.3) 14 (53.8) 1 (3.8) 0.665 19 (73.1) 6 (23.1) 1 (3.8) 0.662 10 (38.5) 12 (46.2) 4 (15.4) 0.562 17 (65.4) 7 (26.9) 2 (7.7) 0.926
No 96 (42.9) 91 (40.6) 37 (16.5) 101 (45.1) 105 (46.9) 18 (8.0) 180 (80.4) 39 (17.4) 5 (2.2) 111 (49.6) 84 (37.5) 29 (12.9) 143 (63.8) 67 (29.9) 14 (6.2)
Nausea Yes 8 (33.3) 11 (45.8) 5 (20.8) 0.582 9 (37.5) 14 (58.3) 1 (4.2) 0.504 17 (70.8) 6 (25.0) 1 (4.2) 0.516 9 (37.5) 14 (58.3) 1 (4.2) 0.080 16 (66.7) 6 (25.0) 2 (8.3) 0.829
No 99 (43.8) 92 (40.7) 35 (15.5) 103 (45.6) 105 (46.5) 18 (8.0) 182 (80.5) 39 (17.3) 5 (2.4) 112 (49.6) 82 (36.3) 32 (14.2) 144 (63.7) 68 (30.1) 14 (6.2)
Vomiting Yes 8 (44.4) 6 (33.3) 4 (22.2) 0.679 6 (33.3) 11 (61.1) 1 (5.6) 0.492 16 (88.9) 2 (11.1) 0 (0.0) 0.552 9 (50.0) 9 (50.0) 0 (0.0) 0.197 13 (72.2) 4 (22.2) 1 (5.6) 0.747
No 99 (42.7) 7 (41.8) 36 (15.5) 106 (45.7) 108 (46.6) 18 (7.8) 183 (78.9) 43 (18.5) 6 (2.6) 112 (48.3) 87 (37.5) 33 (14.2) 147 (63.4) 70 (30.2) 15 (6.5)
Parageusia Yes 7 (58.3) 3 (25.0) 2 (16.7) 0.468 5 (41.7) 6 (50.0) 1 (8.3) 0.974 9 (75.0) 3 (25.0) 0 (0.0) 0.712 8 (66.7) 4 (33.3) 0 (0.0) 0.270 7 (58.3) 5 (41.7) 0 (0.0) 0.475
No 100 (42.0) 100 (42.0) 38 (16.0) 107 (45.0) 113 (47.5) 18 (7.6) 190 (79.8) 42 (17.6) 6 (2.5) 113 (47.5) 92 (38.7) 33 (13.9) 153 (64.3) 69 (29.0) 16 (6.7)
Hypertension Yes 16 (36.4) 19 (43.2) 9 (20.5) 0.541 17 (38.6) 24 (54.5) 3 (6.8) 0.595 31 (70.5) 12 (27.3) 1 (2.3) 0.211 19 (43.2) 20 (45.5) 5 (11.4) 0.569 28 (63.6) 13 (29.5) 3 (6.8) 0.992
No 91 (44.2) 84 (40.8) 31 (15.0) 95 (46.1) 95 (46.1) 16 (7.8) 168 (81.6) 33 (16.0) 5 (2.4) 102 (49.5) 76 (36.9) 28 (13.6) 132 (64.1) 61 (29.6) 16 (6.3)
Diabetes Yes 18 (40.9) 21 (47.7) 5 (11.4) 0.518 22 (50.0) 18 (40.9) 4 (9.1) 0.612 35 (79.5) 8 (18.2) 1 (2.3) 0.998 17 (38.6) 20 (45.5) 7 (15.9) 0.360 29 (65.9) 12 (27.3) 3 (6.8) 0.931
No 89 (43.2) 82 (39.8) 35 (17.0) 90 (43.7) 101 (49.0) 15 (7.3) 164 (79.6) 37 (18.0) 5 (2.4) 104 (50.5) 76 (36.9) 26 (12.6) 131 (63.6) 62 (30.1) 13 (6.3)
Asthma Yes 6 (42.9) 5 (35.7) 3 (21.4) 0.826 7 (50.0) 7 (50.0) 0 (0.0) 0.539 10 (71.4) 3 (21.4) 1 (7.1) 0.447 5 (35.7) 6 (42.9) 3 (21.4) 0.514 9 (64.3) 3 (21.4) 2 (14.3) 0.412
No 101 (42.8) 98 (41.5) 37 (15.7) 105 (44.5) 112 (47.5) 19 (8.1) 189 (80.1) 42 (17.8) 5 (2.1) 116 (49.2) 90 (38.1) 30 (12.7) 151 (64.0) 71 (30.1) 14 (5.9)
Cardiovascular disease Yes 9 (37.5) 13 (54.2) 2 (8.3) 0.327 13 (54.2) 9 (37.5) 2 (8.3) 0.575 19 (79.2) 3 (12.5) 2 (8.3) 0.114 9 (37.5) 11 (45.8) 4 (16.7) 0.528 14 (58.3) 9 (37.5) 1 (4.2) 0.638
No 98 (43.4) 90 (39.8) 38 (16.8) 99 (43.8) 110 (48.7) 17 (7.5) 180 (79.6) 42 (18.6) 4 (1.8) 112 (49.6) 85 (37.6) 29 (12.8) 146 (64.6) 65 (28.8) 15 (6.6)
Chronic renal disease Yes 17 (43.6) 15 (38.5) 7 (17.9) 0.905 24 (61.5) 10 (25.6) 5 (12.8) 0.010 33 (84.6) 6 (15.4) 0 (0.0) 0.489 18 (46.2) 19 (48.7) 2 (5.1) 0.164 27 (69.2) 9 (23.1) 3 (7.7) 0.612
No 90 (42.7) 88 (41.7) 33 (15.6) 88 (41.7) 109 (51.7) 14 (6.6) 166 (78.7) 39 (18.5) 6 (2.8) 103 (48.8) 77 (36.5) 31 (14.7) 133 (63.0) 65 (30.8) 13 (6.2)
Malignancy Yes 3 (30.0) 4 (40.0) 3 (30.0) 0.432 6 (60.0) 3 (30.0) 1 (10.0) 0.524 8 (80.0) 2 (20.0) 0 (0.0) 0.872 3 (30.0) 5 (50.0) 2 (20.0) 0.482 7 (70.0) 1 (10.0) 2 (20.0) 0.110
No 104 (43.3) 99 (41.2) 37 (15.4) 106 (44.2) 116 (48.3) 18 (7.5) 191 (79.6) 43 (17.9) 6 (2.5) 118 (49.2) 91 (37.9) 31 (12.9) 153 (63.7) 73 (30.4) 14 (5.8)



Severe and critical patients (group III)
Gender Male 17 (27.9) 37 (60.7) 7 (11.5) 0.159 21 (34.4) 31 (50.8) 9 (14.8) 0.360 42 (68.9) 16 (26.2) 3 (4.9) 0.810 34 (55.7) 20 (32.8) 7 (11.5) 0.966 41 (67.2) 16 (26.2) 4 (6.6) 0.987
Female 14 (48.3) 13 (44.8) 2 (6.9) 8 (27.6) 19 (65.5) 2 (6.9) 21 (72.4) 6 (20.7) 2 (6.9) 17 (58.6) 9 (31.0) 3 (10.3) 19 (65.5) 8 (27.6) 2 (6.9)
Fever Yes 14 (26.9) 32 (61.5) 6 (11.5) 0.211 19 (36.5) 28 (53.8) 5 (9.6) 0.482 35 (67.3) 15 (28.8) 2 (3.8) 0.417 25 (48.1) 21 (40.4) 6 (11.5) 0.124 36 (69.2) 14 (26.9) 2 (3.8) 0.451
No 17 (44.7) 18 (47.4) 3 (7.9) 10 (26.3) 22 (57.9) 6 (15.8) 28 (73.7) 7 (18.4) 3 (7.9) 26 (68.4) 8 (21.1) 4 (10.5) 24 (63.2) 10 (26.3) 4 (10.5)
Sore throat Yes 11 (42.3) 11 (42.3) 4 (15.4) 0.238 6 (23.1) 17 (65.4) 3 (11.5) 0.450 17 (65.4) 8 (30.8) 1 (3.8) 0.637 13 (50.0) 9 (34.6) 4 (15.4) 0.621 18 (69.2) 7 (26.9) 1 (3.8) 0.789
No 20 (31.2) 39 (60.9) 5 (7.8) 23 (35.9) 33 (51.6) 8 (12.5) 46 (71.9) 14 (21.9) 4 (6.2) 38 (59.4) 20 (31.2) 6 (9.4) 42 (65.6) 17 (26.6) 5 (7.8)
Dry cough Yes 13 (29.5) 26 (59.1) 5 (11.4) 0.621 16 (36.4) 24 (54.5) 4 (9.1) 0.559 26 (59.1) 14 (31.8) 4 (9.1) 0.070 23 (52.3) 15 (34.1) 6 (13.6) 0.644 27 (61.4) 14 (31.8) 3 (6.8) 0.543
No 18 (39.1) 24 (52.2) 4 (8.7) 13 (28.3) 28 (56.5) 7 (15.2) 37 (80.4) 8 (17.4) 1 (2.2) 28 (60.9) 14 (30.4) 4 (8.7) 33 (71.7) 10 (21.7) 3 (6.5)
Headache Yes 1 (10.0) 8 (80.0) 1 (10.0) 0.208 4 (40.0) 6 (60.0) 0 (0.0) 0.443 6 (60.0) 3 (30.0) 1 (10.0) 0.704 5 (50.0) 3 (30.0) 2 (20.0) 0.636 6 (60.0) 3 (30.0) 1 (10.0) 0.857
No 30 (37.5) 42 (52.5) 8 (10.0) 25 (31.2) 44 (55.0) 11 (13.8) 57 (71.2) 19 (23.8) 4 (5.0) 46 (57.5) 26 (32.5) 8 (10.0) 54 (67.5) 21 (26.2) 5 (6.2)
Shortness of breath Yes 11 (18.6) 41 (69.5) 7 (11.9) ˂ 0.001 23 (39.0) 30 (50.8) 6 (10.2) 0.157 39 (66.1) 16 (27.1) 4 (6.8) 0.513 30 (50.8) 22 (37.3) 7 (11.9) 0.290 41 (69.5) 15 (25.4) 3 (5.1) 0.623
No 20 (64.5) 9 (29.0) 2 (6.5) 6 (19.4) 20 (64.5) 5 (16.1) 24 (77.4) 6 (19.4) 1 (3.2) 21 (67.7) 7 (22.6) 3 (9.7) 19 (61.3) 9 (29.0) 3 (9.7)
Diarrhea Yes 5 (45.5) 6 (54.5) 0 (0.0) 0.428 3 (27.3) 7 (63.6) 1 (9.1) 0.842 6 (54.5) 4 (36.4) 1 (9.1) 0.487 5 (45.5) 4 (36.4) 2 (18.2) 0.635 8 (72.7) 3 (27.3) 0 (0.0) 0.636
No 26 (32.9) 44 (55.7) 9 (11.4) 26 (32.9) 43 (54.4) 10 (12.2) 57 (72.2) 18 (22.8) 4 (5.1) 46 (58.2) 25 (31.6) 8 (10.1) 52 (65.8) 21 (26.6) 6 (7.6)
Myalgia Yes 8 (47.1) 8 (47.1) 1 (5.8) 0.450 4 (23.5) 8 (47.1) 5 (29.4) 0.054 15 (88.2) 2 (11.8) 0 (0.0) 0.170 14 (82.4) 2 (11.8) 1 (5.9) 0.058 11 (64.7) 5 (29.4) 1 (5.9) 0.956
No 23 (31.5) 42 (57.5) 8 (11.0) 25 (34.2) 42 (57.5) 6 (8.2) 48 (65.8) 20 (27.4) 5 (6.8) 37 (50.7) 27 (37.0) 9 (12.3) 49 (67.1) 19 (26.0) 5 (6.8)
Fatigue Yes 9 (29.0) 19 (61.3) 3 (9.7) 0.709 7 (22.6) 19 (61.3) 5 (16.1) 0.327 20 (64.5) 9 (29.0) 2 (6.5) 0.712 15 (48.4) 13 (41.9) 3 (9.7) 0.360 21 (67.7) 8 (25.8) 2 (6.5) 0.988
No 22 (37.3) 31 (52.5) 6 (10.2) 22 (37.3) 31 (52.5) 6 (10.2) 43 (72.9) 13 (22.0) 3 (5.1) 36 (61.0) 16 (27.1) 7 (11.9) 39 (66.1) 16 (27.1) 4 (6.8)
Nausea Yes 9 (60.0) 6 (40.0) 0 (0.0) 0.050 5 (33.3) 7 (46.7) 3 (20.0) 0.562 13 (86.7) 1 (6.7) 1 (6.7) 0.214 8 (53.3) 5 (33.3) 2 (13.3) 0.941 10 (66.7) 5 (33.3) 0 (0.0) 0.472
No 22 (29.3) 44 (58.7) 9 (12.0) 24 (32.0) 43 (57.3) 8 (10.7) 50 (66.7) 21 (28.0) 4 (5.3) 43 (57.3) 24 (32.0) 8 (10.7) 50 (66.7) 19 (25.3) 6 (8.0)
Vomiting Yes 4 (364) 6 (54.5) 1 (9.1) 0.987 4 (36.4) 7 (63.6) 0 (0.0) 0.418 4 (36.4) 6 (54.5) 1 (9.1) 0.031 4 (36.4) 5 (45.5) 2 (18.2) 0.340 7 (63.6) 4 (36.4) 0 (0.0) 0.523
No 27 (34.2) 44 (55.7) 8 (10.1) 25 (31.6) 43 (54.4) 11 (13.9) 59 (74.7) 16 (20.3) 4 (5.1) 47 (59.5) 24 (30.4) 8 (10.1) 53 (67.1) 20 (25.3) 6 (7.6)
Parageusia Yes 7 (26.9) 16 (61.5) 3 (11.5) 0.630 6 (23.1) 17 (65.4) 3 (11.5) 0.450 19 (73.1) 7 (26.9) 0 (0.0) 0.337 13 (50.0) 11 (42.3) 2 (7.7) 0.401 19 (73.1) 5 (19.2) 2 (7.7) 0.594
No 24 (37.5) 34 (53.1) 6 (9.4) 23 (35.9) 33 (51.6) 8 (12.5) 44 (68.8) 15 (23.4) 5 (7.8) 38 (59.4) 18 (28.1) 8 (12.5) 41 (64.1) 19 (29.7) 4 (6.2)
Hypertension Yes 18 (40.0) 24 (53.3) 3 (6.7) 0.389 15 (33.3) 24 (53.3) 6 (13.3) 0.902 30. (66.7) 13 (28.9) 2 (4.4) 0.586 25 (55.6) 15 (33.3) 5 (11.1) 0.973 29 (64.4) 14 (31.1) 2 (4.4) 0.497
No 13 (28.9) 26 (57.8) 6 (13.3) 14 (31.1) 26 (57.8) 5 (11.1) 33 (73.3) 9 (20.0) 3 (6.7) 26 (57.8) 14 (31.1) 5 (11.1) 31 (68.9) 10 (22.2) 4 (8.9)
Diabetes Yes 12 (37.5) 19 (59.4) 1 (3.1) 0.271 10 (31.2) 18 (56.2) 4 (12.5) 0.989 23 (71.9) 6 (18.8) 3 (9.4) 0.370 19 (59.4) 11 (34.4) 2 (6.2) 0.551 21 (65.6) 9 (28.1) 2 (6.2) 0.970
No 19 (32.8) 31 (53.4) 8 (13.8) 19 (32.8) 32 (55.2) 7 (12.1) 40 (69.0) 16 (27.6) 2 (3.4) 32 (55.2) 18 (31.0) 8 (13.8) 39 (67.2) 15 (25.9) 4 (6.9)
Asthma Yes 6 (40.0) 5 (33.3) 4 (26.7) 0.034 7 (46.7) 7 (46.7) 1 (6.7) 0.391 13 (86.7) 1 (6.7) 1 (6.7) 0.214 9 (60.0) 6 (40.0) 0 (0.0) 0.305 7 (46.7) 6 (40.0) 2 (13.3) 0.176
No 25 (33.3) 45 (60.0) 5 (6.7) 22 (29.3) 43 (57.3) 10 (13.3) 50 (66.7) 21 (28.0) 4 (5.3) 42 (56.0) 23 (30.7) 10 (13.3) 53 (70.7) 18 (24.0) 4 (5.3)
Cardiovascular disease Yes 7 (63.6) 4 (36.4) 0 (0.0) 0.075 1 (9.1) 8 (72.7) 2 (18.2) 0.211 8 (72.7) 3 (27.3) 0 (0.0) 0.687 7 (63.6) 3 (27.3) 1 (9.1) 0.883 8 (72.7) 2 (18.2) 1 (9.1) 0.772
No 24 (30.4) 46 (58.2) 9 (11.4) 28 (35.4) 42 (53.2) 9 (11.4) 55 (69.6) 19 (24.1) 5 (6.3) 44 (55.7) 26 (32.9) 9 (11.4) 52 (65.8) 22 (27.8) 5 (6.3)
Chronic renal disease Yes 7 (28.0) 15 (60.0) 3 (12.0) 0.712 8 (32.0) 10 (40.0) 7 (28.0) 0.014 21 (84.0) 4 (16.0) 0 (0.0) 0.142 14 (56.0) 9 (36.0) 2 (8.0) 0.795 20 (80.0) 4 (16.0) 1 (4.0) 0.250
No 24 (36.9) 35 (53.8) 6 (9.2) 21 (32.3) 40 (61.5) 4 (6.2) 42 (64.6) 18 (27.7) 5 (7.7) 37 (56.9) 20 (30.8) 8 (12.3) 40 (61.5) 20 (30.8) 5 (7.7)
Malignancy Yes 4 (40.0) 5 (50.0) 1 (10.0) 0.922 2 (20.0) 5 (50.0) 3 (30.0) 0.174 10 (100.0) 0)0.0) 0 (0.0) 0.090 5 (50.0) 4 (40.0) 1 (10.0) 0.856 5 (50.0) 4 (40.0) 1 (10.0) 0.495
No 27 (33.8) 45 (56.2) 8 (10.0) 27 (33.8) 45 (56.2) 8 (10.0) 53 (66.2) 22 (27.5) 5 (6.2) 46 (57.5) 25 (31.2) 9 (11.2) 55 (68.8) 20 (25.0) 5 (6.2)

Bold items indicate an statistically significant levels.

As presented in Table 7 , remarkable differences were detected in BsmI genotypic distribution between mild/moderate patients with a positive/negative history of chronic renal disease in three genetic models, including recessive, overdominant, and codominant (P < 0.05). Similarly, significant discrepancies were identified in both allelic and genotypic distributions of EcoRV between mild/moderate patients with a positive history of diabetes versus cases with no diabetes, in all suggested genetic models. Accordingly, declined ratios of “EE + Ee vs. ee", “EE + ee vs. Ee", and “E vs. e" were seen in group II cases with diabetes versus group II cases without diabetes.

Table 7.

Significant association of VDR gene polymorphisms with some clinical symptom and comorbidities in COVID-19 suffered patients.

Genetic models P- value Odds ratio (95% CI)
Mild/moderate patients
BsmI and chronic renal disease
 Dominant BB + Bb vs. bb 0.189 0.48 (0.16–1.43)
bb vs. BB + Bb 2.08 (0.70–6.25)
 Recessive bb + Bb vs. BB 0.024 0.45 (0.22–0.90)
BB vs. bb + Bb 2.22 (1.11–4.55)
 Overdominant Bb vs. BB + bb 0.004 0.32 (0.15–0.70)
BB + bb vs. Bb 3.13 (1.43–6.67)
 Codominant bb vs. BB 0.636 1.31 (0.43–4.00)
Bb vs. BB 0.007 0.34 (0.15–0.74)
 Allelic B vs. b 0.234 1.39 (0.81–2.41)
b vs. B 0.72 (0.42–1.24)
EcoRV and diabetes
 Dominant EE + Ee vs. ee ˂ 0.001 0.19 (0.08–0.49)
ee vs. EE + Ee 5.26 (2.04–12.50)
 Recessive ee + Ee vs. EE ˂ 0.001 4.45 (2.13–9.29)
EE vs. ee + Ee 0.23 (0.11–0.47)
 Overdominant Ee vs. EE + ee 0.034 2.04 (1.06–3.93)
EE + ee vs. Ee 0.49 (0.26–0.94)
 Codominant ee vs. EE ˂ 0.001 10.17 (3.54–29.21)
Ee vs. EE 0.001 3.57 (1.65–7.75)
 Allelic E vs. e ˂ 0.001 0.31 (0.19–0.50)
e vs. E 3.23 (2.00–5.26)



Severe and critical patients
ApaI and shortness of breath
 Dominant AA + Aa vs. aa 0.423 0.51 (0.10–2.63)
aa vs. AA + Aa 1.96 (0.38–10.00)
 Recessive aa + Aa vs. AA ˂ 0.001 7.93 (2.96–21.25)
AA vs. aa + Aa 0.13 (0.05–0.34)
 Overdominant Aa vs. AA + aa ˂ 0.001 5.57 (2.15–14.44)
AA + aa vs. Aa 0.18 (0.07–0.47)
 Codominant aa vs. AA 0.037 6.36 (1.12–36.08)
Aa vs. AA ˂ 0.001 8.28 (2.96–23.21)
 Allelic A vs. a 0.001 0.30 (0.15–0.62)
a vs. A 3.33 (1.61–6.67)
ApaI and asthma
 Dominant AA + Aa vs. aa 0.029 0.20 (0.05–0.85)
aa vs. AA + Aa 5.00 (1.18–20.00)
 Recessive aa + Aa vs. AA 0.621 0.75 (0.24–2.34)
AA vs. aa + Aa 1.33 (0.43–4.17)
 Overdominant Aa vs. AA + aa 0.065 0.33 (0.10–1.07)
AA + aa vs. Aa 3.03 (0.94–10.00)
 Codominant aa vs. AA 0.137 3.33 (0.68–16.32)
Aa vs. AA 0.240 0.46 (0.13–1.67)
 Allelic A vs. a 0.493 0.76 (0.34–1.68)
a vs. A 1.32 (0.60–2.94)
BsmI and chronic renal disease
 Dominant BB + Bb vs. bb 0.009 0.17 (0.04–0.64)
bb vs. BB + Bb 5.88 (1.56–25.00)
 Recessive bb + Bb vs. BB 0.978 1.01 (0.38–2.72)
BB vs. bb + Bb 0.99 (0.37–2.63)
 Overdominant Bb vs. BB + bb 0.069 0.42 (0.16–1.07)
BB + bb vs. Bb 2.38 (0.94–6.25)
 Codominant bb vs. BB 0.043 4.59 (1.05–20.06)
Bb vs. BB 0.440 0.66 (0.23–1.91)
 Allelic B vs. b 0.176 0.63 (0.33–1.23)
b vs. B 1.59 (0.81–3.03)
FokI and hypertension
 Dominant FF + Ff vs. ff 0.013 0.22 (0.07–0.72)
ff vs. FF + Ff 4.55 (1.39–14.29)
 Recessive ff + Ff vs. FF 0.655 1.22 (0.51–2.94)
FF vs. ff + Ff 0.82 (0.34–1.96)
 Overdominant Ff vs. FF + ff 0.093 0.49 (0.21–1.13)
ff + FF vs. Ff 2.04 (0.89–4.76)
 Codominant ff vs. FF 0.040 4.00 (1.07–15.01)
Ff vs. FF 0.601 0.78 (0.30–2.00)
 Allelic F vs. f 0.072 0.58 (0.32–1.05)
f vs. F 1.72 (0.95–3.13)
CDX2 and shortness of breath
 Dominant CC + Cc vs. cc 0.009 3.59 (1.37–9.42)
cc vs. CC + Cc 0.28 (0.11–0.73)
 Recessive cc + Cc vs. CC 0.086 0.40 (0.14–1.14)
CC vs. cc + Cc 2.50 (0.88–7.14)
 Overdominant Cc vs. CC + cc 0.433 1.43 (0.58–3.52)
CC + cc vs. Cc 0.70 (0.28–1.72)
 Codominant cc vs. CC 0.012 0.21 (0.07–0.71)
Cc vs. CC 0.452 0.65 (0.21–2.03)
 Allelic C vs. c 0.005 2.47 (1.31–4.66)
c vs. C 0.41 (0.22–0.76)
CDX2 and hypertension
 Dominant CC + Cc vs. cc 0.038 0.36 (0.14–0.94)
cc vs. CC + Cc 2.78 (1.06–7.14)
 Recessive cc + Cc vs. CC 0.649 0.81 (0.33–1.99)
CC vs. cc + Cc 1.24 (0.50–3.03)
 Overdominant Cc vs. CC + cc 0.020 0.36 (0.15–0.85)
CC + cc vs. Cc 2.78 (1.18–6.67)
 Codominant cc vs. CC 0.286 1.84 (0.60–5.63)
Cc vs. CC 0.140 0.47 (0.17–1.28)
 Allelic C vs. c 0.297 0.73 (0.41–1.32)
c vs. C 1.37 (0.76–2.44)
CDX2 and diabetes
 Dominant CC + Cc vs. cc 0.014 0.30 (0.12–0.79)
cc vs. CC + Cc 3.33 (1.27–8.33)
 Recessive cc + Cc vs. CC 0.354 1.58 (0.60–4.15)
CC vs. cc + Cc 0.63 (0.24–1.67)
 Overdominant Cc vs. CC + cc 0.161 0.52 (0.21–1.29)
CC + cc vs. Cc 1.92 (0.78–4.76)
 Codominant cc vs. CC 0.046 3.18 (1.02–9.93)
Cc vs. CC 0.890 0.93 (0.31–2.77)
 Allelic C vs. c 0.029 0.50 (0.27–0.93)
c vs. C 2.00 (1.08–3.70)
EcoRV and diabetes
 Dominant EE + Ee vs. ee 0.466 2.30 (0.25–21.47)
ee vs. EE + Ee 0.44 (0.05–4.00)
 Recessive ee + Ee vs. EE 0.033 2.74 (1.08–6.92)
EE vs. ee + Ee 0.41 (0.15–0.93)
 Overdominant Ee vs. EE + ee 0.015 3.12 (1.25–7.76)
EE + ee vs. Ee 0.32 (0.13–0.80)
 Codominant ee vs. EE 0.877 0.83 (0.08–8.43)
Ee vs. EE 0.020 3.06 (1.19–7.85)
 Allelic E vs. e 0.171 0.64 (0.33–1.22)
e vs. E 1.56 (0.82–3.03)

Bold items indicate an statistically significant levels.

Remarkable associations between VDR gene polymorphisms with more clinical variables and comorbidities were represented in group III of COCID-19 patients (Table 5, Table 6). Regarding the signs and symptoms, significant associations were found between ApaI and CDX2 SNPs with shortness of breath, and Tru9I SNP with vomiting (P ˂ 0.001, P = 0.022, and P = 0.031, respectively). Our data showed a significant association of both ApaI genotypes and alleles with shortness of breath in all proposed genetic models except the dominant model (Table 7). Our results also revealed remarkable associations of CDX2 genotypes and alleles with shortness of breath in dominant and codominant genetic models (Table 7). It was shown that rates of “CC + Cc vs. cc" and “C vs. c" were higher in severe/critical patients with shortness of breath, while the frequency of “cc vs. CC + Cc”, “cc vs. CC", and “c vs. C" were lower.

Additionally, significant associations were observed between VDR gene variants and more comorbidities in severe/critical COVID-19 patients, including ApaI and asthma (P = 0.034), BsmI and chronic renal disease (P = 0.014), FokI and hypertension (P = 0.027), CDX2 and both hypertension and diabetes (P = 0.36 and P = 0.42, respectively), EcoRV and diabetes (P = 0.045) (Table 5, Table 6). As presented in Table 7, a significant association was found between ApaI and asthma in severe/critical COVID-19 patients only in the dominant genetic model, in which diminished proportion of the “AA + Aa vs. aa” and elevated proportion of the “aa vs. AA + Aa” were disclosed. Regarding the BsmI SNP, significant associations were found with chronic renal disease in dominant and codominant genetic models. Accordingly, a higher amount of “bb vs. BB + Bb” and “bb vs. BB” were found in severe/critical patients with chronic renal disease than those didn't have this comorbidity, while “BB + Bb vs. bb” was lower. The association of FokI genotypic distribution with hypertension was significant in severe/critical patients in dominant and codominant genetic models. The data revealed a reduced rate of “FF + Ff vs. ff”, but increased rates of the “ff vs. FF + Ff” and “ff vs. FF” in group III patients with hypertension compared to negative hypertension history (Table 7). The results of the present study showed a significant CDX2 genotypic discrepancies in severe/critical patients with hypertension in dominant and overdominant genetic models, as well as cases with diabetes in dominant and codominant models compared to negative cases for these comorbidities (Table 7). Significantly, higher frequency of “cc vs. CC + Cc” and “CC + cc vs. Cc" were observed in group III COVID-19 patients with hypertension than patients with negative history of hypertension, while the frequency of “CC + Cc vs. cc" and “Cc vs. CC + cc” were considered to be reduced. Additionally, the results showed significantly increased amounts of “cc vs. CC + Cc”, “cc vs. CC", and “c vs. C", and decreased frequency of “CC + Cc vs. cc" and “C vs. c" in severe/critical COVID-19 patients with diabetes compared to patients without diabetes. Finally, we observed significant association of EcoRV with diabetes in severe/critical patients in recessive, overdominant, and codominant genetic models, in which higher proportions of “ee + Ee vs. EE", “Ee vs. EE + ee”, and “Ee vs. EE" were found in group III patients with diabetes than negative diabetes cases, while proportions of the “EE vs. ee + Ee” and “EE + ee vs. Ee" were lower (Table 7).

To improve the validity of achieved results, we evaluate the potential association of selected VDR SNPs with signs/symptoms and with comorbidities in all symptomatic COVID-19 patients by combining whole data, regardless of the types of COVID-19 (N = 340 cases, N = 500 cases, respectively). As presented in Table 8 , interesting associations of VDR SNPs with symptoms and comorbidities were found that are briefly mentioned: ApaI with fever and asthma (P = 0.001 and P = 0.023, respectively), BsmI with chronic renal disease (P = 0.029), Tru9I with shortness of breath and hypertension (P = 0.040 and P = 0.003, respectively), FokI with fever and hypertension (P = 0.042 and P = 0.045, respectively), CDX2 with headache, hypertension, and diabetes (P = 0.019, P = 0.005 and P = 0.015, respectively), and EcoRV with diabetes (P ˂ 0.001).

Table 8.

Association of VDR gene polymorphisms- related genotypes with clinical data in COVID-19 patients with positive criteria of signs and symptoms.

5′ end's VDR polymorphisms
Variables Status FokI
CDX2
EcoRV
FF Ff ff P CC Cc cc P EE Ee ee P
Gender Male 76 (37.4) 96 (47.3) 31 (15.3) 0.766 67 (33.0) 89 (43.8) 47 (23.2) 0.217 99 (48.8) 86 (42.4) 18 (8.9) 0.468
Female 50 (36.5) 62 (45.3) 25 (18.2) 56 (40.9) 58 (42.3) 23 (16.8) 74 (54.0) 55 (40.1) 8 (5.8)
Fever Yes 65 (33.7) 88 (45.6) 40 (20.7) 0.042 70 (36.3) 88 (45.6) 35 (18.1) 0.390 91 (47.2) 84 (43.5) 18 (9.3) 0.190
No 61 (41.5) 70 (47.6) 16 (10.9) 53 (36.1) 59 (40.1) 35 (23.8) 82 (55.8) 57 (38.8) 8 (5.4)
Sore throat Yes 37 (34.3) 51 (47.2) 20 (18.5) 0.685 33 (30.6) 56 (51.9) 19 (17.6) 0.091 56 (51.9) 44 (40.7) 8 (7.4) 0.970
No 89 (38.4) 107 (46.1) 36 (15.5) 90 (38.8) 91 (39.2) 51 (22.0) 117 (50.4) 97 (41.8) 18 (7.8)
Dry cough Yes 66 (35.1) 96 (48.4) 31 (16.5) 0.680 76 (404) 75 (39.9) 37 (19.7) 0.187 101 (53.7) 71 (37.8) 16 (8.5) 0.291
No 60 (39.5) 67 (44.1) 25 (16.4) 47 (30.9) 72 (47.4) 33 (21.7) 72 (47.4) 70 (46.1) 10 (6.6)
Headache Yes 25 (42.4) 26 (44.1) 8 (13.6) 0.607 19 (32.2) 20 (33.9) 20 (33.9) 0.019 26 (44.1) 27 (45.8) 6 (10.2) 0.458
No 101 (35.9) 132 (47.0) 48 (17.1) 104 (37.0) 127 (45.2) 50 (17.8) 147 (52.3) 114 (40.6) 20 (7.1)
Shortness of breath Yes 35 (38.9) 37 (41.1) 18 (20.0) 0.408 30 (33.3) 38 (42.2) 22 (24.4) 0.552 43 (47.8) 37 (41.1) 10 (11.1) 0.340
No 91 (36.4) 121 (48.4) 38 (15.2) 93 (37.2) 109 (43.6) 48 (19.2) 130 (52.0) 104 (41.6) 16 (6.4)
Diarrhea Yes 8 (26.7) 15 (50.0) 7 (23.3) 0.370 8 (26.7) 15 (50.0) 7 (23.3) 0.524 17 (56.7) 11 (36.7) 2 (6.7) 0.802
No 118 (38.1) 143 (46.1) 49 (15.8) 115 (37.1) 132 (42.6) 63 (20.3) 156 (50.3) 130 (41.9) 24 (7.7)
Myalgia Yes 26 (39.2) 40 (50.6) 13 (16.5) 0.650 31 (39.2) 33 (41.8) 15 (19.0) 0.800 45 (57.0) 29 (36.7) 5 (6.3) 0.462
No 100 (38.3) 118 (45.2) 43 (16.5) 92 (35.2) 114 (43.7) 55 (21.1) 128 (49.0) 112 (42.9) 21 (8.0)
Fatigue Yes 24 (42.1) 19 (33.3) 14 (24.6) 0.057 24 (42.1) 24 (42.1) 9 (15.8) 0.484 32 (56.1) 22 (38.6) 3 (5.3) 0.601
No 102 (36.0) 139 (49.1) 42 (14.8) 99 (35.0) 123 (43.5) 61 (21.6) 141 (49.8) 119 (42.0) 23 (8.1)
Nausea Yes 14 (35.9) 18 (46.2) 7 (17.9) 0.963 12 (30.8) 17 (43.6) 10 (25.6) 0.636 19 (48.7) 16 (41.0) 4 (10.3) 0.805
No 112 (37.2) 140 46.5() 49 (16.3) 111 (36.9) 130 (43.2) 60 (19.9) 154 (51.2) 125 (41.5) 22 (7.3)
Vomiting Yes 6 (20.7) 18 (62.1) 5 (17.2) 0.138 10 (34.5) 12 (41.4) 7 (24.1) 0.885 11 (37.9) 16 (55.2) 2 (6.9) 0.286
No 120 (38.6) 140 (45.0) 51 (16.4) 113 (36.3) 135 (43.4) 63 (20.3) 162 (52.1) 125 (40.2) 24 (7.7)
Parageusia Yes 17 (44.7) 17 (44.7) 4 (10.5) 0.444 13 (34.2) 15 (39.5) 10 (26.3) 0.648 18 (47.4) 18 (47.4) 2 (5.3) 0.677
No 109 (36.1) 141 (46.7) 52 (17.2) 110 (36.4) 132 (43.7) 60 (19.9) 155 (51.3) 123 (40.7) 24 (7.9)
Hypertension Yes 28 (31.5) 39 (43.8) 22 (24.7) 0.045 28 (31.5) 32 (36.0) 29 (32.6) 0.005 40 (44.9) 42 (47.2) 7 (7.9) 0.408
No 98 (39.0) 119 (47.4) 34 (13.5) 95 (37.8) 115 (45.8) 41 (16.3) 133 (53.0) 99 (39.4) 19 (7.6)
Diabetes Yes 26 (34.2) 35 (46.1) 15 (19.7) 0.653 20 (26.3) 32 (42.1) 24 (31.6) 0.015 20 (26.3) 45 (59.2) 11 (14.5) ˂ 0.001
No 100 (37.9) 123 (46.6) 41 (15.5) 103 (39.0) 115 (43.6) 46 (17.4) 153 (58.0) 96 (36.4) 15 (5.7)
Asthma Yes 12 (41.4) 12 (41.4) 5 (17.2) 0.840 11 (37.9) 13 (44.8) 5 (17.2) 0.897 14 (48.3) 13 (44.8) 2 (6.9) 0.927
No 114 (36.7) 146 (46.9) 51 (16.4) 112 (36.0) 134 (43.1) 65 (20.9) 159 (51.1) 128 (41.2) 24 (7.7)
Cardiovascular disease Yes 18 (51.4) 12 (34.3) 5 (14.3) 0.171 15 (42.9) 16 (45.7) 4 (11.4) 0.345 22 (62.9) 11 (31.4) 2 (5.7) 0.326
No 108 (35.4) 146 (47.9) 51 (16.7) 108 (35.4) 131 (43.0) 66 (21.6) 151 (49.5) 130 (42.6) 24 (7.9)
Chronic renal disease Yes 24 (37.5) 26 (40.6) 16 (21.9) 0.371 25 (39.1) 27 (42.2) 12 (18.8) 0.847 32 (50.0) 29 (45.3) 3 (4.7) 0.550
No 102 (37.0) 132 (47.8) 42 (15.2) 98 (35.5) 120 (43.5) 58 (21.0) 141 (51.1) 112 (40.6) 23 (8.3)
Malignancy Yes 6 (30.0) 11 (55.0) 3 (15.0) 0.724 10 (50.0) 10 (50.0) 0 (0.0) 0.057 13 (65.0) 5 (25.0) 2 (10.0) 0.305
No 120 (37.5) 147 (45.9) 53 (16.6) 113 (35.3) 137 (42.8) 70 (21.9) 160 (50.0) 136 (42.5) 24 (7.5)



3′ end's VDR polymorphisms
Variables Status ApaI
BsmI
Tru9I
TaqI
BglI
AA Aa aa P BB Bb bb P UU Uu uu P TT Tt tt P GG Gg gg P
Gender Male 76 (37.4) 98 (48.3) 29 (14.3) 0.295 83 (40.9) 99 (48.8) 21 (10.3) 0.484 154 (75.9) 45 (22.2) 4 (2.0) 0.127 102 (50.2) 72 (35.5) 29 (14.3) 0.519 137 (67.5) 54 (26.6) 12 (5.9) 0.425
Female 62 (45.3) 55 (40.1) 20 (14.4) 58 (42.3) 70 (51.1) 9 (6.6) 108 (78.8) 22 (16.1) 7 (5.1) 70 (51.1) 53 (38.7) 14 (10.2) 83 (60.6) 44 (32.1) 10 (7.3)
Fever Yes 63 (32.6) 102 (52.8) 28 (14.5) 0.001 86 (44.6) 93 (48.2) 14 (7.3) 0.289 144 (74.6) 44 (22.8) 5 (2.6) 0.214 92 (47.7) 78 (40.4) 23 (11.9) 0.278 123 (63.7) 58 (30.1) 12 (6.2) 0.842
No 75 (51.0) 51 (34.7) 21 (14.3) 55 (37.4) 76 (51.7) 16 (10.9) 118 (80.3) 23 (15.6) 6 (4.1) 80 (54.4) 47 (32.0) 20 (13.6) 97 (66.0) 40 (27.2) 10 (6.8)
Sore throat Yes 48 (44.4) 44 (40.7) 16 (14.8) 0.539 43 (39.8) 56 (51.9) 9 (8.3) 0.863 85 (78.7) 17 (15.7) 6 (5.6) 0.139 54 (50.0) 38 (35.2) 16 (14.8) 0.702 68 (63.0) 33 (30.6) 7 (6.5) 0.887
No 90 (38.8) 109 (47.0) 33 (14.2) 98 (42.2) 113 (48.7) 21 (9.1) 177 (76.3) 50 (21.6) 5 (2.2) 118 (50.9) 87 (37.5) 27 (11.6) 152 (65.5) 65 (28.0) 15 (6.5)
Dry cough Yes 75 (39.9) 85 (45.2) 28 (14.9) 0.941 80 (42.6) 94 (50.0) 14 (7.4) 0.598 137 (72.9) 44 (23.4) 7 (3.7) 0.123 95 (50.5) 65 (34.6) 28 (14.9) 0.328 119 (63.3) 57 (30.3) 12 (6.4) 0.794
No 63 (41.4) 68 (44.7) 21 (13.8) 61 (40.1) 75 (49.3) 16 (10.5) 125 (82.2) 23 (15.1) 4 (2.6) 77 (50.7) 60 (39.5) 15 (9.9) 101 (66.4) 41 (27.0) 10 (6.6)
Headache Yes 26 (44.1) 21 (35.6) 12 (20.3) 0.187 26 (44.1) 28 (47.5) 5 (8.5) 0.905 46 (78.0) 10 (16.9) 3 (5.1) 0.595 28 (47.5) 23 (39.0) 8 (13.6) 0.869 40 (67.8) 17 (28.8) 2 (3.4) 0.562
No 112 (39.9) 132 (47.0) 37 (13.2) 115 (40.9) 141 (50.2) 25 (8.9) 216 (76.9) 57 (20.3) 8 (2.8) 144 (51.2) 102 (36.3) 35 (12.5) 180 (64.1) 81 (28.8) 20 (7.1)
Shortness of breath Yes 33 (36.7) 46 (51.1) 11 (12.2) 0.389 38 (42.2) 42 (46.7) 10 (11.1) 0.616 61 (67.8) 24 (26.7) 5 (5.6) 0.040 44 (48.9) 35 (38.9) 11 (12.2) 0.888 64 (71.1) 21 (23.3) 5 (5.6) 0.330
No 105 (42.0) 107 (42.8) 38 (14.4) 103 (41.2) 127 (50.8) 20 (8.0) 201 (80.4) 43 (17.2) 6 (2.4) 128 (51.2) 90 (36.0) 32 (12.8) 156 (62.4) 77 (30.8) 17 (6.8)
Diarrhea Yes 15 (50.0) 12 (40.0) 3 (10.0) 0.510 11 (36.7) 15 (50.0) 4 (13.3) 0.624 22 (73.3) 7 (23.3) 1 (3.3) 0.869 15 (50.0) 9 (30.0) 6 (20.0) 0.403 22 (73.3) 8 (26.7) 0 (0.0) 0.278
No 123 (39.7) 141 (45.5) 46 (14.8) 130 (41.9) 154 (49.7) 28 (8.4) 240 (77.4) 60 (19.4) 10 (3.2) 157 (50.6) 116 (37.4) 37 (11.9) 198 (63.9) 90 (29.0) 22 (7.1)
Myalgia Yes 34 (43.0) 38 (48.1) 7 (8.9) 0.276 30 (38.0) 39 (49.4) 10 (12.7) 0.364 63 (79.7) 16 (20.3) 0 (0.0) 0.179 43 (54.4) 29 (36.7) 7 (8.9) 0.480 56 (70.9) 17 (21.5) 6 (7.6) 0.257
No 104 (39.8) 115 (44.1) 42 (16.1) 11 (42.5) 130 (49.8) 20 (7.7) 199 (76.2) 51 (19.5) 11 (4.2) 129 (49.4) 96 (36.8) 36 (13.8) 164 (62.8) 81 (31.0) 16 (6.1)
Fatigue Yes 18 (31.6) 31 (54.4) 8 (14.0) 0.257 25 (43.9) 30 (52.6) 2 (3.5) 0.301 40 (70.2) 13 (22.8) 4 (7.0) 0.151 23 (404) 27 (47.4) 7 (12.3) 0.172 40 (70.2) 14 (24.6) 3 (5.3) 0.637
No 120 (42.4) 122 (43.1) 41 (14.5) 116 (41.0) 139 (49.1) 28 (9.9) 222 (78.4) 54 (19.1) 7 (2.5) 149 (52.7) 98 (34.6) 36 (12.7) 180 (63.6) 84 (29.7) 19 (6.7)
Nausea Yes 17 (43.6) 17 (43.6) 5 (12.8) 0.907 14 (35.9) 21 (53.8) 4 (10.3) 0.747 30 (76.9) 7 (17.9) 2 (5.1) 0.757 17 (43.6) 19 (48.7) 3 (7.7) 0.224 26 (66.7) 11 (28.2) 2 (5.1) 0.926
No 121 (40.2) 136 (45.2) 44 (14.6) 127 (42.2) 148 (49.2) 26 (8.6) 232 (77.1) 60 (19.9) 9 (3.0) 155 (51.5) 106 (35.2) 40 (13.3) 194 (64.5) 87 (28.9) 20 (6.6)
Vomiting Yes 14 (48.3) 9 (31.0) 6 (20.7) 0.259 8 (27.6) 19 (65.5) 2 (6.9) 0.202 21 (72.4) 6 (20.7) 2 (6.9) 0.492 13 (44.8) 12 (41.4) 4 (13.8) 0.809 21 (72.4) 7 (24.1) 1 (3.4) 0.613
No 124 (39.9) 144 (46.3) 43 (13.8) 133 (42.8) 150 (48.2) 28 (9.0) 241 (77.5) 61 (19.6) 9 (2.9) 159 (51.1) 113 (36.3) 39 (12.5) 199 (64.0) 91 (29.3) 21 (6.8)
Parageusia Yes 14 (36.8) 19 (50.0) 5 (13.2) 0.806 11 (28.9) 23 (60.5) 4 (10.5) 0.251 28 (73.7) 10 (26.3) 0 (0.0) 0.302 21 (55.3) 15 (39.5) 2 (5.3) 0.374 26 (68.4) 10 (26.3) 2 (5.3) 0.869
No 124 (41.1) 134 (44.4) 44 (14.6) 130 (43.0) 146 (48.3) 26 (8.6) 234 (77.5) 57 (18.9) 11 (3.6) 151 (50.0) 110 (36.4) 41 (13.6) 194 (64.2) 88 (29.1) 20 (6.6)
Hypertension Yes 35 (39.3) 42 (47.2) 12 (13.5) 0.883 34 (38.2) 46 (51.7) 9 (10.1) 0.729 60 (67.4) 26 (29.2) 3 (3.4) 0.030 43 (48.3) 35 (39.3) 11 (12.4) 0.841 58 (65.2) 26 (29.2) 5 (5.6) 0.930
No 103 (41.0) 111 (44.2) 37 (14.7) 107 (42.6) 123 (49.0) 21 (8.4) 202 (80.5) 41 (16.3) 8 (3.2) 129 (51.4) 90 (35.9) 32 (12.7) 162 (64.5) 72 (28.7) 17 (6.8)
Diabetes Yes 30 (39.5) 40 (52.6) 6 (7.9) 0.124 32 (42.1) 36 (47.4) 8 (10.5) 0.803 58 (76.3) 14 (18.4) 4 (5.3) 0.513 36 (47.4) 31 (40.8) 9 (11.8) 0.711 50 (65.8) 21 (27.6) 5 (6.6) 0.967
No 108 (40.9) 113 (42.8) 43 (16.3) 109 (41.3) 133 (50.4) 22 (8.3) 204 (77.3) 53 (20.1) 7 (2.7) 136 (51.5) 94 (35.6) 34 (12.9) 170 (64.4) 77 (29.2) 17 (6.4)
Asthma Yes 11 (37.9) 9 (31.0) 9 (31.0) 0.023 12 (41.4) 12 (41.4) 5 (17.2) 0.224 24 (82.8) 4 (13.8) 1 (3.4) 0.704 16 (55.5) 10 (34.5) 3 (10.3) 0.857 14 (48.3) 11 (37.9) 4 (13.8) 0.088
No 127 (40.8) 144 (46.3) 40 (12.9) 129 (41.5) 157 (50.5) 25 (8.0) 238 (76.5) 63 (20.3) 10 (3.2) 156 (50.2) 115 (37.0) 40 (12.9) 206 (66.2) 87 (28.0) 18 (5.8)
Cardiovascular disease Yes 15 (42.9) 16 (45.7) 4 (11.4) 0.863 14 (40.0) 16 (45.7) 9 (14.3) 0.481 25 (71.4) 9 (25.7) 1 (2.9) 0.640 15 (42.9) 13 (37.1) 7 (20.0) 0.345 25 (71.4) 8 (22.9) 2 (5.7) 0.674
No 123 (40.3) 137 (44.9) 45 (14.8) 127 (41.6) 153 (50.2) 25 (8.2) 237 (77.7) 58 (19.0) 10 (3.3) 157 (51.5) 112 (36.7) 36 (11.8) 195 (63.9) 90 (29.5) 20 (6.6)
Chronic renal disease Yes 26 (40.6) 29 (45.3) 9 (14.1) 0.996 30 (46.9) 24 (37.5) 10 (15.6) 0.029 54 (84.4) 10 (15.6) 0 (0.0) 0.152 33 (51.6) 27 (42.2) 4 (6.2) 0.202 46 (71.9) 13 (20.3) 5 (7.8) 0.243
No 112 (40.6) 124 (44.9) 40 (14.5) 111 (40.2) 145 (52.5) 20 (7.2) 208 (75.4) 57 (20.7) 11 (4.0) 139 (50.4) 98 (35.5) 39 (14.1) 174 (63.0) 85 (30.8) 17 (6.2)
Malignancy Yes 5 (25.0) 12 (60.0) 3 (15.0) 0.310 10 50.0() 8 (40.0) 2 (20.0) 0.667 15 (75.0) 4 (20.0) 1 (5.0) 0.897 6 (30.0) 12 (60.0) 2 (10.0) 0.081 14 (70.0) 4 (20.0) 2 (10.0) 0.584
No 133 (41.6) 141 (44.1) 46 (14.4) 131 (40.9) 161 (50.3) 28 (8.8) 247 (77.2) 63 (19.7) 10 (3.1) 166 (51.9) 113 (35.3) 41 (12.8) 206 (64.4) 94 (29.4) 20 (6.2)

Bold items indicate an statistically significant levels.

As detailed in Table 9 , the observed associations of genotypic and allelic VDR polymorphisms with signs, symptoms, and comorbidities of COVID-19 patients (regardless of the group of disease) strongly depend on the genetic models. For instance, significant associations of both allelic and genotypic distributions with the fever of COVID-19 patients were detected in recessive, overdominant, and codominant genetic models. Additionally, we found a remarkable association of ApaI genotypic distribution with asthma in dominant and overdominant genetic models, but not in recessive and overdominant models, as well as in allelic distribution. Similar to our finding in the earlier section, significant differences in the distribution of genotypes were revealed between COVID-19 patients with the chronic renal disease compared to negative cases only in dominant and overdominant genetic models. Accordingly, a higher frequency of “bb vs. BB + Bb” and “BB + bb vs. Bb” were found, while the frequency of “BB + Bb vs. bb” and “Bb vs. BB + bb” were decreased. Despite the no significant association of Tru9I polymorphism with clinical characteristics in various groups of COVID-19 patients, significant associations of Tru9I with shortness of breath in the combined population of COVID-19 patients were found in recessive, codominant, as well as allelic genetic models. According to Table 9, increased rates of “uu + Uu vs. UU", “Uu vs. UU", and “u vs. U", and decreased rates of “UU vs. uu + Uu” and “U vs. u" were seen in COVID-19 patients with shortness of breath versus those who didn't have this symptom. The higher frequency of FokI variant showed significant associations with fever and hypertension in dominant, codominant, and allelic models, but not in recessive and overdominant genetic models (Table 9).

Table 9.

Significant association of VDR gene polymorphisms with some clinical symptom and comorbidities in COVID-19 patients.

Genetic models P- value Odds ratio (95% CI)
ApaI and fever
Dominant AA + Aa vs. aa 0.954 0.98 (0.53–1.81)
aa vs. AA + Aa 1.02 (0.55–1.89)
Recessive aa + Aa vs. AA < 0.001 2.15 (1.38–3.34)
AA vs. aa + Aa 0.47 (0.30–0.73)
Overdominant Aa vs. AA + aa < 0.001 2.11 (1.36–3.28)
AA + aa vs. Aa 0.47 (0.31–0.74)
Codominant aa vs. AA 0.168 1.59 (0.82–3.06)
Aa vs. AA < 0.001 2.38 (1.48–3.83)
Allelic A vs. a 0.013 0.67 (0.49–0.92)
a vs. A 1.49 (1.09–2.04)



ApaI and asthma
Dominant AA + Aa vs. aa 0.011 0.33 (0.14–0.77)
aa vs. AA + Aa 3.03 (1.30–7.14)
Recessive aa + Aa vs. AA 0.761 1.13 (0.52–2.47)
AA vs. aa + Aa 0.89 (0.41–1.92)
Overdominant Aa vs. AA + aa 0.119 0.52 (0.23–1.18)
AA + aa vs. Aa 1.92 (0.85–4.35)
Codominant aa vs. AA 0.049 2.60 (1.01–6.72)
Aa vs. AA 0.484 0.72 (0.29–1.80)
Allelic A vs. a 0.114 0.65 (0.38–1.11)
a vs. A 1.54 (0.90–2.63)



BsmI and chronic renal disease
Dominant BB + Bb vs. bb 0.038 0.42 (0.19–0.95)
bb vs. BB + Bb 2.38 (1.05–5.26)
Recessive bb + Bb vs. BB 0.331 0.76 (0.44–1.32)
BB vs. bb + Bb 1.32 (0.76–2.27)
Overdominant Bb vs. BB + bb 0.032 0.54 (0.31–0.95)
BB + bb vs. Bb 1.85 (1.05–3.23)
Codominant bb vs. BB 0.161 1.85 (0.78–4.37)
Bb vs. BB 0.104 0.61 (0.34–1.11)
Allelic B vs. b 0.853 0.96 (0.64–1.44)
b vs. B 1.04 (0.69–1.56)



Tru9I and shortness of breath
Dominant UU + Uu vs. uu 0.159 0.42 (0.12–1.41)
uu vs. UU + Uu 2.38 (0.71–8.33)
Recessive uu + Uu vs. UU 0.016 1.95 (1.14–3.35)
UU vs. uu + Uu 0.51 (0.30–0.88)
Overdominant Uu vs. UU + uu 0.055 1.75 (0.99–3.10)
UU + uu vs. Uu 0.57 (0.32–1.01)
Codominant uu vs. UU 0.105 2.75 (0.81–9.31)
Uu vs. UU 0.038 1.84 (1.03–3.27)
Allelic U vs. u 0.008 0.53 (0.33–0.85)
u vs. U 1.89 (1.18–3.03)



Tru9I and hypertension
Dominant UU + Uu vs. uu 0.933 0.94 (0.25–3.64)
uu vs. UU + Uu 1.06 (0.28–4.00)
Recessive uu + Uu vs. UU 0.013 1.99 (1.16–3.43)
UU vs. uu + Uu 0.50 (0.29–0.86)
Overdominant Uu vs. UU + uu 0.010 2.11 (1.20–3.72)
UU + uu vs. Uu 0.47 (0.27–0.83)
Codominant uu vs. UU 0.737 1.26 (0.32–4.91)
Uu vs. UU 0.009 2.14 (1.21–3.77)
Allelic U vs. u 0.026 0.58 (0.37–0.94)
u vs. U 1.72 (1.06–2.70)



FokI and fever
Dominant FF + Ff vs. ff 0.017 0.47 (0.25–0.87)
ff vs. FF + Ff 2.13 (1.15–4.00)
Recessive ff + Ff vs. FF 0.140 1.40 (0.90–2.18)
FF vs. ff + Ff 0.71 (0.46–1.11)
Overdominant Ff vs. FF + ff 0.711 0.92 (0.60–1.42)
ff + FF vs. Ff 1.09 (0.70–1.67)
Codominant ff vs. FF 0.014 2.35 (1.19–4.62)
Ff vs. FF 0.490 1.18 (0.74–1.89)
Allelic F vs. f 0.020 0.69 (0.50–0.94)
f vs. F 1.45 (1.06–2.00)



FokI and hypertension
Dominant FF + Ff vs. ff 0.016 0.48 (0.26–0.87)
ff vs. FF + Ff 2.08 (1.15–3.85)
Recessive ff + Ff vs. FF 0.204 1.40 (0.83–2.33)
FF vs. ff + Ff 0.71 (0.43–1.21)
Overdominant Ff vs. FF + ff 0.560 0.87 (0.53–1.41)
ff + FF vs. Ff 1.15 (0.71–1.89)
Codominant ff vs. FF 0.019 2.27 (1.15–4.48)
Ff vs. FF 0.628 1.15 (0.66–2.00)
Allelic F vs. f 0.028 0.68 (0.48–0.96)
f vs. F 1.47 (1.04–2.08)



CDX2 and headache
Dominant CC + Cc vs. cc 0.006 0.42 (0.23–0.78)
cc vs. CC + Cc 2.38 (1.28–4.35)
Recessive cc + Cc vs. CC 0.485 1.24 (0.68–2.25)
CC vs. cc + Cc 0.81 (0.44–1.47)
Overdominant Cc vs. CC + cc 0.113 0.62 (0.35–1.12)
CC + cc vs. Cc 1.61 (0.89–2.86)
Codominant cc vs. CC 0.031 2.19 (1.07–4.47)
Cc vs. CC 0.668 0.86 (0.44–1.70)
Allelic C vs. c 0.037 0.66 (0.44–0.98)
c vs. C 1.51 (1.02–2.27)



CDX2 and hypertension
Dominant CC + Cc vs. cc 0.001 0.40 (0.23–0.70)
cc vs. CC + Cc 2.50 (1.43–4.35)
Recessive cc + Cc vs. CC 0.282 1.33 (0.79–2.22)
CC vs. cc + Cc 0.75 (0.45–1.27)
Overdominant Cc vs. CC + cc 0.108 0.66 (0.40–1.09)
CC + cc vs. Cc 1.52 (0.92–2.50)
Codominant cc vs. CC 0.007 2.40 (1.27–4.53)
Cc vs. CC 0.845 0.94 (0.53–1.68)
Allelic C vs. c 0.009 0.63 (0.45–0.89)
c vs. C 1.59 (1.12–2.22)



CDX2 and diabetes
Dominant CC + Cc vs. cc 0.008 0.46 (0.26–0.82)
cc vs. CC + Cc 2.17 (1.22–3.85)
Recessive cc + Cc vs. CC 0.044 1.79 (1.06–3.16)
CC vs. cc + Cc 0.56 (0.32–0.94)
Overdominant Cc vs. CC + cc 0.823 0.94 (0.56–1.58)
CC + cc vs. Cc 1.06 (0.63–1.79)
Codominant cc vs. CC 0.005 2.69 (1.35–5.35)
Cc vs. CC 0.254 1.43 (0.77–2.66)
Allelic C vs. c 0.003 0.58 (0.40–0.84)
c vs. C 1.72 (1.19–2.50)



EcoRV and diabetes
Dominant EE + Ee vs. ee 0.014 0.36 (0.16–0.81)
ee vs. EE + Ee 2.78 (1.24–6.25)
Recessive ee + Ee vs. EE < 0.001 3.86 (2.19–6.80)
EE vs. ee + Ee 0.26 (0.15–0.46)
Overdominant Ee vs. EE + ee < 0.001 2.54 (1.51–4.28)
EE + ee vs. Ee 0.39 (0.23–0.66)
Codominant ee vs. EE < 0.001 5.61 (2.27–13.89)
Ee vs. EE < 0.001 3.59 (2.00–6.44)
Allelic E vs. e < 0.001 0.40 (0.27–0.58)
e vs. E 2.50 (1.72–3.70)

Bold items indicate an statistically significant levels.

Moreover, CDX2 polymorphism was disclosed to have significant associations with three clinical features, including headache, hypertension, and diabetes. In respect of headache and hypertension, significant differences were illustrated in the allelic distribution, as well as in the dominant and codominant models for genotypic distributions, but not in recessive and overdominant genetic models (Table 9). According to both headache and hypertension features, the results revealed elevated ratios of “cc vs. CC + Cc”, “cc vs. CC", and “c vs. C", but decreased ratios of “CC + Cc vs. cc" and “C vs. c" in COVID-19 patients with these clinical features against to subjects without these variables. Furthermore, CDX2 was indicated to possess a strong association with diabetes in both allelic and all genetic models, except in the overdominant model in combined samples of COVID-19 patients (Table 9). Accordingly, higher rates of the “cc vs. CC + Cc”, “cc + Cc vs. CC".“ cc vs. CC", and “c vs. C" were recognized in COVID-19 patients with diabetes than patients without this comorbidity, nevertheless, lower rates of the “ CC + Cc vs. cc", “ CC vs. cc + Cc”, and “ C vs. c" were illustrated. The last finding was the association between EcoRV allelic and genotypic distribution and diabetes in all proposed genetic models (Table 9). Our results revealed increased rates of “ee vs. EE + Ee”, “ee + Ee vs. EE", “Ee vs. EE + ee”, “ee vs. EE", “Ee vs. EE", and “e vs. E", and decreased rates of the “ EE + Ee vs. ee “, “ EE vs. ee + Ee “, “ EE + ee vs. Ee “, and “ E vs. e “ were seen in combined samples of COVID-19 subjects with diabetes compared to those with no diabetes.

4. Discussion

The wide spectrum of clinical manifestations of the resulting COVID-19 range from silent (asymptomatic) or mild symptoms of the upper respiratory tract such as familiar cold symptoms (fever, stuffy nose, cough, Sore throat, weakness) bronchitis to severe pneumonia with ARDS and death (Singhal, 2020). Many Risk factors recognized for this coronavirus include advanced age, male gender, comorbidities, race, obesity, hypertension, diabetes, geographic region, and ethnicity (Mendy et al., 2020). More importantly, several previous studies disclosed the association of specific human genetic variants with the predisposition of individuals to develop severe disease or susceptibility to infection (Anastassopoulou et al., 2020; Hou et al., 2020; Latini et al., 2020; Wang et al., 2020; Gómez et al., 2020). Some of the identified associations between genetic factors and different severity of COVID-19 or variable susceptibility to SARS-CoV-2 are ABO blood group, ACE2, APOE, HLA, IFITM3, TLR7, TMEM189-UBE2V1, TMPRSS2.

Mounting investigations have revealed the role of vitamin D deficiency as a pathogenic factor of COVID-19, leading to an increase in the predisposition and severity of individuals, especially via exacerbating acute lung injury and ARDS (Faul et al., 2020; Carpagnano et al., 2020; Parekh et al., 2013). Several types of research highlighted that patients with ARDS and also COVID-19 cases are even more vitamin D deficient than control subjects (Dancer et al., 2015; Thickett et al., 2015; Park et al., 2018; Quesada-Gomez et al., 2020). Furthermore, more vitamin D deficiency [25(OH) D levels:< 50 nmol/L] and insufficiency [25(OH) D levels:50–75 nmol/L)] was demonstrated in regions highly affected by COVID-19, such as Iran (Ebadi et al., 2019; Tabrizi et al., 2018). Undoubtedly, a complex relationship can be proposed between vitamin D and COVID-19, in which many environmental and genetic factors are implicated. Among environmental factors, seasonal variation in sun exposure, geographic latitudes, air pollution, and darker skin influence vitamin D formation by sunlight in vitro (Wacker and Holick, 2013). Intriguingly, In Chicago, more than half of COVID-19 cases and around 70% of COVID-19 deaths were observed in African-American individuals (Yancy, 2020) who are at a greater risk for vitamin D deficiency (Alzaman et al., 2016). The actions of vitamin D are largely mediated by its intranuclear receptor, VDR, which is extensively distributed in respiratory epithelial cells and immune cells (B cell, T cell, macrophages, and monocytes). The expression and regulation of VDR itself are influenced by several mechanisms, including cell-type-specific transcription factors (TFs), auto-regulation by vitamin D, methylation of its primary promoter, and genetic variations (Saccone et al., 2015). Genetic variations in the VDR gene such as SNPs might alter the function VD/VDR pathway in bronchial epithelium and immune-regulatory functions, which consequently influence the susceptibility to a large number of diverse conditions (Valdivielso and Fernandez, 2006; Laplana et al., 2018; Mohammadi et al., 2020; Mehrabani et al., 2019) and possibly COVID-19.

In the present study, the association of eight SNPs in the VDR gene with the severity of COVID-19 patients was evaluated. Our data showed significant associations for some of the SNP-related alleles and/or genotypes in one or more genetic models. FokI polymorphism in the exon 2 at the 5′ end of the VDR gene is referred to as start codon polymorphism (SCP), in which the presence of the “T” allele (the mutated “f” allele) results in the translation of a 3 amino acid longer VDR protein, while the “C” allele (the wild type “F” allele) produces shorter VDR protein that is associated with 1.7-fold increased transcriptional activity (Köstner et al., 2009; Whitfield et al., 2001; Jurutka et al., 2000; Colin et al., 2000). In the FokI variant, results showed this SNP as a pinpointed associated factor with COVID-19; in which “f” (mutated) allele frequencies were intended to be higher in symptomatic and severe/critical patients compared with asymptomatic COVID-19 affected people. Hence, it can be suggested that the “f” allele, is positively associated with signs, symptoms, and possibly the severity of COVID-19 affected peoples. FokI genotypic distributions illustrated important results based on recessive and codominant genetic models in COVID-19 individuals, including the decreased vulnerability of “FF” genotype compared with combined “Ff + ff” genotypes, and increased susceptibility of “ff” patients versus “FF” affected subjects to represent signs, symptoms, and possibly more serious outcomes. However, there were no significant differences between “FF” and “Ff” patients for the clinical characteristics of COVID-19. The meta-analyses showed an association of FokI polymorphism with susceptibility to virus infection (McNally et al., 2014). This association could be contributed to the changes in TFIIB-VDR interaction, transcription efficiency, the effects of FokI polymorphism on immune cell behavior (van Etten et al., 2007). Based on a meta-analysis by Laplana et al., FokI polymorphism was associated with viral infections, wherein the TT genotype and T allele were reported to be risk factors for infections with enveloped viruses, including RSV (Laplana et al., 2018). In this line, the risk f-allele may have a lower transcription of VDR decreasing the efficiency of the vitamin D pathway by hampering the binding of vitamin D to VDR and affecting the expression of vitamin D responsive genes. Further, no significant differences were disclosed in FokI allelic and genotypic distributions between mild/moderate and asymptomatic groups, as well as between mild/moderate and severe/critical patients.

The Cdx-2 site in the 1a promoter region of the VDR gene is a functional binding site for the transcription factor Cdx-2. G to A substitution polymorphism at this site has been found to alter the transcription of the VDR gene, whereby the A-allele increases binding to the Cdx-2 protein and transcription activity of the VDR promoter compared with the G allele (Fang et al., 2003). According to the CDX2 results, “c” minor allele frequency was higher in symptomatic and severe/critical patients against asymptomatic COVID-19 cases, while “C” major allele rates were lower. Thus, the alleles “c” and “C” can be introduced as risk and protective factors, respectively, for signs, symptoms, and maybe the severity of the COVID-19. CDX2 genotypic distributions illustrated more interesting findings based on dominant, recessive, and codominant genetic models in COVID-19 patients, including protective effects of “CC” versus “Cc + cc”, susceptible effects of “cc” versus both “CC + Cc” and “CC” to have clinical features and likely severity of the disease. Cdx2 is considered as a functional polymorphism of the VDR gene that has been demonstrated to impact the immune system alter the risk of contracting certain infectious illnesses (e.g., tuberculosis and rubella) (Meyer and Bornman, 2018; Ovsyannikova et al., 2010). Nevertheless, no substantial link has been established between this SNP and autoimmune disorders such as T1D, MS, vitiligo, or psoriasis (Dickinson et al., 2009; Zhou et al., 2014; Frederiksen et al., 2013; Aydıngöz et al., 2012). Although it is uncertain why the polymorphism is connected to illnesses like tuberculosis, numerous studies have connected this association to VDR methylation, vitamin D-mediated control of chemokine-positive T cells, and impact adaptive cytokine responses (Meyer and Bornman, 2018; Ovsyannikova et al., 2010; Harishankar and Selvaraj, 2017).

The EcoRV polymorphism (rs4516035), like CDX2, is found in the promoter region of the VDR gene and is thought to play a role in the anticancer immune response. EcoRV (5′ to exon 1a) is a regulatory region SNPs that can affect VDR transcription via TF binding differences (Halsall et al., 2004). In the presented study, EcoRV allelic and genotypic distributions unveiled several intriguing findings. Firstly, EcoRV minor allele “e” frequencies were remarkably inclined to increase in symptomatic, mild/moderate, and severe/critical patients compared to asymptomatic COVID-19 patients, while major allele “E” rates were decreased. Therefore, negative and positive associations of “E” and “e” alleles, respectively, with clinical outcomes of COVID-19 can be proposed. Nonetheless, no significant discrepancy was found in allelic frequencies between mild/moderate and severe/critical patients. Accordingly, genetic model-based genotypic distributions of EcoRV polymorphism highlighted the protective role of “EE” vs. “Ee + ee”, vulnerable effects of “Ee” versus “EE + ee”, and “Ee” versus “EE”. Amazingly, we didn't found any significant differences in the distribution of “ee” and “EE” genotypes among different clinical groups. Furthermore, increased frequencies of “Ee” versus “EE + ee” and “Ee” versus “EE” in severe/critical compared to mild/moderate patients, obviously demonstrated the important role of heterozygous “Ee” in the severity of COVID-19 patients. It is previously reported that EcoRv is correlated with optimal bone density, cancer risk, diabetes, and susceptibility to HIV-1 infection (Halsall et al., 2004; Ghodsi et al., 2021).

The ApaI (rs7975232) intronic variation is anticipated to impact splice site alterations, which may change VDR translation. This variation is common, as indicated by 734 and 16,751 homozygous mutants in the 1000G and ExAC databases, respectively (Hussain et al., 2019). ApaI allelic frequencies, determined as major “A” and minor “a” alleles, didn't show significant differences between various paired groups of COVID-19. The present study highlighted that the “AA” genotype made COVID-19 affected people more prone to possess signs and symptoms versus both “Aa + aa” and “Aa” genotypes based on paired-groups of the symptomatic-asymptomatic and mild/moderate-asymptomatic comparisons. Additionally, heterozygous “Aa” patients were more protected to show signs and symptoms compared to combined “AA + aa” genotypes. This finding was interestingly opposite between severe/critical and mild/moderate groups, in which a rising risk of severity was demonstrated in patients with “Aa” genotype compared to “AA + aa” genotypes. This could be explained by the involvement of several factors determining the severity of the disease and might not be directly related to ApaI effects. Association of ApaI with different conditions including cancers, type 1 diabetes, asthma, multiple sclerosis, and several autoimmune diseases has previously been reported (Clendenen et al., 2008; Cheon et al., 2015; Mohammadi et al., 2020; Wjst, 2005).

BsmI polymorphism was revealed not to have any significant differences in allelic and genotypic frequencies between asymptomatic COVID-19 patients and other groups, including mild/moderate, severe/critical, and also all symptomatic patients. However, remarkable discrepancies were observed in allelic and genotypic distributions between mild/moderate and severe/critical COVID-19 suffered individuals. Our finding disclosed that minor allele “b” acts as a predisposition factor to COVID-19 severity, but major allele “B” has a protective effect. Moreover, genetic model-based genotypic distributions illustrated that patients with the “BB” genotype versus combined “bb + Bb” genotypes have decreased risk to develop more serious forms of COVID-19. However, “Bb” symptomatic heterozygotes showed elevated vulnerability to have more seriously COVID-19 than combined “BB + Bb” genotypes. VDR has an essential function in regulating the immune system in macrophages, dendritic cells, neutrophils, B cells, natural killer (NK) cells, and T lymphocyte. Therefore, these findings could be interpreted that VDR BsmI polymorphism has a significant role in susceptibility to and in the progression of viral infections such as COVID-19.

The SNP Tru9I didn't show any significant differences in allelic distribution between paired-group comparisons, except between severe/critical and mild/moderate groups, in which major “U” and minor “u” alleles were described as protective and risk factors, respectively. Tru9I genotypic frequencies didn't exhibit any significant association with clinical manifestations and also severity COVID-19. TaqI and BglI variants-related allelic and genotypic frequencies showed no significant association with clinical manifestations and also severity of COVID-19 affected peoples based on any genetic models in the present study. TaqI is a synonymous mutation at codon 352 in exon 9 at the 3′ end of the VDR gene, in which “T” and “t” alleles were identified as absent and presence of the restriction site, respectively. The TT genotype has been reported to be associated with lower circulating levels of active vitamin D3 (Morrison et al., 1994; Hustmyer et al., 1993; Ma et al., 1998). ApaI, BsmI, Tru9I, and BglI are located in intron 8 at the 3′ end of the VDR gene, which are considered silent SNPs. These polymorphisms do not change the amino acid sequence of the encoded protein, however, they may affect gene expression through the regulation of mRNA stability or linkage disequilibrium with other SNPs affecting the susceptibility to diseases (Jurutka et al., 2001).

Evaluating the potential association of VDR gene SNPs with signs and symptoms of COVID-19 patients, especially respiratory complications, surely highlights the more detailed importance of these variants in the severity of the disease. Despite the significant associations of some VDR gene variants with signs and symptoms of mild/moderate COVID-19 patients, amazing findings were pinpointed in group III. Accordingly, we found a strong association between both allelic and genotypic distributions of ApaI and CDX2 SNPs with shortness of breath. Regarding the ApaI, we found that major “A” and minor allele “a” provide a protective and susceptible effect, respectively, in severe/critical patients. According, our findings disclosed that severe/critical COVID-19 patients with “Aa” genotype and then “aa” genotype are more at risk of shortness of breath than “AA” patients. The minor “c” and major “C” alleles of CDX2 were found to have positive and negative associations with symptomatic and severe/critical COVID-19 groups, respectively. Moreover, negative association of “CC” genotype versus combined “Cc + cc” genotypes, positive associations of “cc” genotype versus both combined “CC + Cc” genotypes, and “CC” genotype to have clinical features and likely severity of disease are suggested. Nevertheless, “cc” versus both combined “CC + Cc” genotypes and “CC” genotype revealed a strong protective effect against shortness of breath. Unfortunately, we can't provide a rational explanation for these contradictory findings, therefore, it needs to be re-evaluated in other studies with larger sample sizes, in other ethnicities, and geographical regions.

Despite the high prevalence of conflicting results in previous investigations, we separately assessed the potential association of these VDR gene SNPs with some comorbidities including hypertension, diabetes, asthma, cardiovascular disease, chronic renal disease, and malignancy in various COVID-19 groups to further clarify how these genetic variants affect the prognosis of COVID-19 patients. No significant association was found between VDR gene variants and comorbidities in the asymptomatic COVID-19 group, while a strong association of VDR gene SNPs was seen with some of these conditions in mild/moderate and severe/critical groups.

Our results revealed that mild/moderate COVID-19 patients with the “BB” genotype are more prone to chronic renal disease, while patients with “Bb” are more protective. Therefore, it can be proposed that homozygotes subjects (“BB” and “bb”) are at increased risk of chronic renal disease than heterozygotes in mild/moderate patients. Unlikely, we found an increased risk of the “bb” genotype versus the combined “BB + Bb” and “BB” genotype, and no significant discrepancy was observed between the distribution of the “Bb” and “BB” to have chronic renal disease in severe/critical COVID-19 patients. Consequently, we can suggest that the “Bb” genotype provides a protective role to have chronic renal disease in both mild/moderate and severe/critical COVID-19 patients, but the effects of “BB” and “bb” genotypes entirely depend on the stage of the disease. Regarding the EcoRV variant and diabetes in mild/moderate COVID-19 patients, we observed a negative association of the “E” allele and a positive association of the “e” allele. Also, our data revealed the protective effect of the “EE” genotype, but predisposing impacts of “ee” genotype, as well as increased risk of “Ee” genotype versus combined “EE + ee” and “EE” genotypes against diabetes. Therefore, it can be proposed that mild/moderate COVID-19 patients with 0, 1, and 2 alleles of minor allele “e” have a low, intermediate, and high risk of diabetes, respectively. Similar findings were observed in severe/critical patients, however, the distribution of “EE” and “ee” didn't show any remarkable difference. Overall, it can be argued that how the EcoRV variant is associated with diabetes depends entirely on the stage of COVID-19 disease, wherein the additive and overdominant genetic model better explains the observed findings in mild/moderate and severe/critical groups, respectively.

In addition to EcoRV, CDX2 polymorphism has also been disclosed to have a significant association with diabetes in severe/critical COVID-19 patients. The major “C” and minor “c” alleles exhibited a negative and positive association with diabetes, respectively. Moreover, it was demonstrated that severe/critical patients with the “cc” genotype are more susceptible to have diabetes. Also, the CDX2 was recognized to have an association with hypertension, in which severe/critical COVID-19 patients with genotype “cc” have an increased risk for hypertension. Collectively, it can be proposed that the “cc” genotype causes an increased risk on severe/critical COVID-19 to exhibit both diabetes and hypertension comorbidities. Similarly, FokI SNP illustrated a remarkable association with hypertension in severe/critical COVID-19 patients, in which elevated risk of hypertension was detected in “ff” genotype. ApaI genotypes were deciphered to possess a significant association with asthma, in which severe/critical COVID-19 patients with “aa” genotype strongly have increased risk than “AA + Aa” patients. Briefly, our data highlighted that ApaI SNP is associated with respiratory complications, including shortness of breath and asthma in severe/critical COVID-19 patients more likely based on overdominant and dominant genetic models, respectively.

To evaluate the reproducibility of the results and increase the accuracy of the study, the association of VDR gene SNPs with clinical outcomes and comorbidities was examined, regardless of the severity grouping of COVID-19 patients that in turn led to obtaining a larger sample size. Here, we found a significant association of VDR gene polymorphisms with several clinical outcomes of COVID-19 patients, including the association of ApaI and FokI variants with fever, Tru9I with shortness of breath, and CDX2 with the headache. By comparing these findings with the results described earlier, it is clear that these associations are quietly different. ApaI allelic and genotypic frequencies revealed that alleles “A” and “a” contribute to decreased and increased susceptibility of COVID-19 patients to fever, respectively. Our data revealed that patients with genotype “AA”, are more protected to exhibit fever than “Aa + aa” patients, but the “Aa” patients are more susceptible to exhibit fever than “AA + aa”, “AA” and “aa” genotypes. All of these findings pinpointed that the overdominant genetic model is the most likely model, in which an increased chance to have a fever might be occurred in heterozygotes compared to both dominant and recessive homozygotes. In respect of FokI SNP, we found that the major “F” allele associate with diminished susceptibility to fever, however the minor “f” allele associate with increased risk. Accordingly, we demonstrated that COVID-19 patients with the “ff” genotype have a higher chance to exhibit fever than “FF + Ff”, “FF”, and “Ff” patients. We didn't find a significant difference in the distribution of “FF” and “Ff” genotypes between patients with positive and negative fever histories. Consequently, the dominant genetic model is the most likely model, in which “ff” homozygotes are more vulnerable to fever than “Ff” heterozygotes and “FF” homozygotes. Our results disclosed that Tru9I major “U” and minor “u” alleles possess protective and predisposing effects to the shortness of breath, respectively. Further, “UU” COVID-19 patients are more protective to shortness of breath than “Uu + uu”, while “Uu” patients are more susceptible to this respiratory complication than COVID-19 subjects with “UU” or “uu” genotypes. Consequently, although no significant difference between “Uu” and combined “UU + uu” was detected, we can propose an overdominant genetic model for this SNP, in which the heterozygotes “Uu” are at elevated risk compared to both “UU” and “uu” homozygotes. The findings of the present study identified the association of CDX2 allelic and genotypic association with headache. It was highlighted that the “C” major allele was negatively associated with headache, but the “c” minor allele was positively associated in COVID-19 patients. Accordingly, we found an increased risk of headache in COVID-19 subjects with “cc” genotype than combined “CC + Cc”, “Cc”, and “CC” genotypes. However, any significant differences in the distribution of “CC” and “Cc” genotypes didn't observe between COVID-19 cases with and without headache though.

The results of VDR gene SNPs association with comorbidities in the combined COVID-19 patient samples regardless of severity groups (N = 500 cases) were interestingly almost consistent with associations found in COVID-19 subgroups. ApaI was identified to associate with asthma in the dominant genetic model, in which COVID-19 patients with the “aa” genotype were at higher risk than “AA + Aa” to have asthma. The “bb” homozygotes of BsmI SNP were more susceptible to chronic renal disease in the combined samples (consists of 500 cases) and severe/critical subgroup, while both “BB” and “bb” genotypes increase the risk of chronic renal disease in mild/moderate group. The association of EcoRV polymorphism with diabetes was disclosed in combined COVID-19 samples and the most likely of proposed genetic models is additive genetic model, similar to mild/moderate group, in which the COVID-19 affected individuals with 0, 1, and 2 alleles of minor allele “e” are at low, intermediate, and high risk of diabetes, respectively, nonetheless, the overdominant model works better in the severe/critical group. Similar to the severe/critical class of COVID-19, we found a significant association of the CDX2 allelic and genotypic distributions with diabetes and hypertension, in which major “C” and minor “c” alleles exhibited a negative and positive association with both diabetes and hypertension, respectively. According to the results, the strongest genetic model is the dominant model, in which COVID-19 patients with the “cc” genotype have an increased risk of both diabetes and hypertension comorbidities compared to “CC + Cc”, “CC”, and “Cc” genotypes. Moreover, we found that FokI's major “F” and minor “f” alleles showed protective and susceptible effects on hypertension in combined COVID-19 samples, respectively. Similar to severe/critical patients, COVID-19 patients with “ff” genotype have elevated risk to hypertension versus “FF + Ff”, “Ff”, and “FF” genotypes. The last detected association between VDR gene variants and comorbidities was an association of Tru9I with hypertension, which was not observed in subtypes of COVID-19 patients. The results disclosed major “U” and minor “u” alleles as susceptible and protective factors for hypertension, respectively. Tru9I genotypic distributions suggested an overdominant genetic model as the most likely model, in which COVID-19 patients with “Uu” genotype had increased risk to hypertension than “UU + uu”, “UU”, “uu” patients.

To appropriately recognize individuals who may require hospital and/or ICU admission, risk stratification based on clinical, radiographic, and laboratory data appears to be essential. The existence of comorbidities is among the most alarming clinical characteristics. Some underlying illnesses such as hypertension, diabetes, lung disease, cardiovascular disease, age may be health issues for severe COVID-19 patients who have poorer outcomes than non-severe COVID-19 patients (Yang et al., 2020). Current evidence from the present study suggests that comorbidities including age, hypertension, diabetes, and chronic renal disease may work as a risk for the worst prognosis of COVID-19 patients. Consistent with previously reported data, our results revealed that severe/critical patients were older than mild/moderate and asymptomatic patients (Williamson et al., 2020). Therefore, a positive association between elder ages and more severity of COVID-19 patients could be proposed. We observed greater frequencies of these diseases in severe/critical patients versus mild/moderate and asymptomatic patients, which is consistent with several reports (Singh et al., 2020; Henry and Lippi, 2020; Pranata et al., 2020). Asthma has been considered as a risk factor that makes people susceptible to more severe COVID-19 illness (Lee et al., 2020). However, managing COVID-19 in severe asthma is difficult, and it's uncertain if individuals with severe asthma are at a higher risk of having the poorest results, at least partially due to safety concerns about biologics and systemic corticosteroids (SCSs) (Adir et al., 2021). Our results showed an increased frequency of asthma conditions in severe/critical patients versus mild/moderate patients. Interestingly, a lower frequency of this condition was observed in mild/moderate patients than asymptomatic COVID-19 cases. Similar to our results, many recent studies revealed the strong positive association of cancer with the severity of COVID-19, even though inconsistent findings were also observed (Zhang et al., 2020b). Intriguingly, our results didn't show any significant discrepancies of cancer frequency between severe/critical and asymptomatic COVID-19 patients. Despite early studies suggested that cancer might be a separate risk factor for severe COVID-19, recent matched researches comparing outcomes between hospitalized cancer patients and matched controls found no statistically significant differences in death (Brar et al., 2020; Klein et al., 2021). As a result, a history of cancer and cancer-directed treatments might not even be associated with a greater risk of the most serious COVID-19 outcomes in hospitalized individuals. A proinflammatory state and a weakened innate immune response are suggested as the common characteristics between these chronic illnesses and infectious diseases, which may be connected etiologically to its pathogenesis. More importantly, the co-existence of multiple comorbidities in patients seems to increase the risk of severity or death in COVID-19 disease. Regarding the signs and symptoms in symptomatic patients, increased significant frequencies of the shortness of breath, fatigue, and parageusia were illustrated in the severe/critical group compared to the mild/moderate group, which is similar to previous investigations (Liu et al., 2020). Breathlessness is a distressing and common symptom in patients with severe illness, and it is thought to be caused by physiological and structural abnormalities in the lungs. The increased ventilatory drive may rationalize our findings since individuals with moderate COVID-19 nevertheless respond physiologically to hypoxia.

5. Conclusion

Vitamin D has been shown to regulate macrophage responses, stopping them from producing excessive amounts of inflammatory cytokines and chemokines, which are common in COVID-19. Therefore, the prevalence and mortality rate of COVID-19 may depend on the modulatory effect of bioavailable Vitamin D levels of individuals, which is determined by the genetic background, such as VDR gene polymorphisms. Therefore, we designed the present study to explore the association of eight VDR gene SNPs with the clinical status and prognosis of COVID-19 patients. We found significant associations of VDR gene variants with several clinical outcomes such as severity and shortness of breath in mild/moderate and severe/critical cases of COVID-19. Nevertheless, the VDR gene SNPs could not be proposed as either independent or dependent risk factors to COVID-19-co-existing conditions, including hypertension, diabetes, asthma, cardiovascular disease, chronic renal disease, and malignancy. Our data showed that some VDR SNPs have a clinical impact on the COVID-19 patients and might be helpful to identify the individuals at high risk of COVID-19 severity in the Iranian population. Moreover, the variations in the prevalence of COVID-19 and its mortality rates among countries may be explained by vitamin D function differed by the VDR polymorphisms. However, the present study is preliminary with partially limited sample size. Thus, further experiments are suggested to identify the role of VDR polymorphisms as the cause-effect of COVID-19 severity in a larger population, in other ethnicities and geographical regions.

Author's Contributions

Asaad Azarnezhad and Rasoul Abdollahzadeh: Conceptualization, Methodology, Funding acquisition, and Project Administration. Mohammad Hossein Shushizadeh, Rasoul Abdollahzadeh, and Asaad Azarnezhad: Data curation, Data Interpretation, and Writing- Original draft preparation. Mina Barazandehrokh and Sepideh Choopani: Data curation, Visualization, Investigation, Reviewing and Editing, and Software, Sahereh Paknahad, Maryam Pirhoushiaran, S.Zahra Makani, Razieh, and Zarifian Yeganeh: Data curation, Data Interpretation, Laboratory works, and revising. Ahmed Al-Kateb and Roozbeh Heidarzadehpilehrood: Reviewing, Editing, Software, Validation, and Revising.

Declaration of competing interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

The authors would like to thank the participants enrolled in this study. The author(s) received no specific funding for this work. We also thank all of the individuals who provided insight and expertise that greatly assisted the research, although they may not agree with all of the interpretations/conclusions of this paper.

References

  1. Abdollahzadeh R., Fard M.S., Rahmani F., Moloudi K., Azarnezhad A. Predisposing role of vitamin D receptor (VDR) polymorphisms in the development of multiple sclerosis: a case-control study. J. Neurol. Sci. 2016;367:148–151. doi: 10.1016/j.jns.2016.05.053. [DOI] [PubMed] [Google Scholar]
  2. Abdollahzadeh R., Moradi Pordanjani P., Rahmani F., Mashayekhi F., Azarnezhad A., Mansoori Y. Association of VDR gene polymorphisms with risk of relapsing-remitting multiple sclerosis in an Iranian Kurdish population. Int. J. Neurosci. 2018;128(6):505–511. doi: 10.1080/00207454.2017.1398158. [DOI] [PubMed] [Google Scholar]
  3. Adir Y., Humbert M., Saliba W. COVID-19 risk and outcomes in adult asthmatics treated with biologics or systemic corticosteroids: nationwide real-world evidence. J. Allergy Clin. Immunol. 2021;148(2):361–367. doi: 10.1016/j.jaci.2021.06.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. J. Infect. Publ. Health. 2020;13(10):1373–1380. doi: 10.1016/j.jiph.2020.06.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Alzaman N.S., Dawson-Hughes B., Nelson J., D’Alessio D., Pittas A.G. Vitamin D status of black and white Americans and changes in vitamin D metabolites after varied doses of vitamin D supplementation. Am. J. Clin. Nutr. 2016;104(1):205–214. doi: 10.3945/ajcn.115.129478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Amrein K., Scherkl M., Hoffmann M., Neuwersch-Sommeregger S., Köstenberger M., Berisha A.T., et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur. J. Clin. Nutr. 2020:1–16. doi: 10.1038/s41430-020-0558-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Anastassopoulou C., Gkizarioti Z., Patrinos G.P., Tsakris A. Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity. Hum. Genom. 2020;14(1):1–8. doi: 10.1186/s40246-020-00290-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Aydıngöz İ.E., Bingül İ., Doğru-Abbasoğlu S., Vural P., Uysal M. Analysis of vitamin D receptor gene polymorphisms in vitiligo. Dermatology. 2012;224(4):361–368. doi: 10.1159/000339340. [DOI] [PubMed] [Google Scholar]
  9. Aygun H. Vitamin D can prevent COVID-19 infection-induced multiple organ damage. Naunyn Schmiedeberg’s Arch. Pharmacol. 2020:1–4. doi: 10.1007/s00210-020-01911-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Biesalski H.K. Vitamin D deficiency and co-morbidities in COVID-19 patients–A fatal relationship? NFS Journal. 2020;20:10–21. [Google Scholar]
  11. Bizzaro G., Antico A., Fortunato A., Bizzaro N. Vitamin D and autoimmune diseases: is vitamin D receptor (VDR) polymorphism the culprit. Isr. Med. Assoc. J. 2017;19(7):438–443. [PubMed] [Google Scholar]
  12. Brar G., Pinheiro L.C., Shusterman M., Swed B., Reshetnyak E., Soroka O., et al. COVID-19 severity and outcomes in patients with Cancer: a matched cohort study. J. Clin. Oncol. 2020:3914–3924. doi: 10.1200/JCO.20.01580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cameron M.J., Bermejo-Martin J.F., Danesh A., Muller M.P., Kelvin D.J. Human immunopathogenesis of severe acute respiratory syndrome (SARS) Virus Res. 2008;133(1):13–19. doi: 10.1016/j.virusres.2007.02.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Carpagnano G.E., Di Lecce V., Quaranta V.N., Zito A., Buonamico E., Capozza E., et al. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. J. Endocrinol. Investig. 2020:1–7. doi: 10.1007/s40618-020-01370-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Channappanavar R., Perlman S., editors. Seminars in Immunopathology. Springer; 2017. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi: 10.1016/S0140-6736(20)30211-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Cheon C.K., Nam H.K., Lee K.H., Kim S.Y., Song J.S., Kim C. Vitamin D receptor gene polymorphisms and type 1 diabetes mellitus in a Korean population. Pediatr. Int. 2015;57(5):870–874. doi: 10.1111/ped.12634. [DOI] [PubMed] [Google Scholar]
  18. Clendenen T.V., Arslan A.A., Koenig K.L., Enquist K., Wirgin I., Ågren Å., et al. Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer. Cancer Lett. 2008;260(1–2):209–215. doi: 10.1016/j.canlet.2007.11.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Colin E.M., Weel A.E., Uitterlinden A.G., Buurman C.J., Birkenhäger J.C., Pols H.A., et al. Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3. Clin. Endocrinol. 2000;52(2):211–216. doi: 10.1046/j.1365-2265.2000.00909.x. [DOI] [PubMed] [Google Scholar]
  20. Dancer R.C., Parekh D., Lax S., D’Souza V., Zheng S., Bassford C.R., et al. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS) Thorax. 2015;70(7):617–624. doi: 10.1136/thoraxjnl-2014-206680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. De Wit E., Van Doremalen N., Falzarano D., Munster V.J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 2016;14(8):523. doi: 10.1038/nrmicro.2016.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Dickinson J.L., Perera D.I., Van der Mei A., Ponsonby A.-L., Polanowski A.M., Thomson R.J., et al. Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 Vitamin D receptor variant in this interaction. Mult. Scler. J. 2009;15(5):563–570. doi: 10.1177/1352458509102459. [DOI] [PubMed] [Google Scholar]
  23. Ebadi M., Bhanji R.A., Mazurak V.C., Lytvyak E., Mason A., Czaja A.J., et al. Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis. Aliment. Pharmacol. Ther. 2019;49(2):173–182. doi: 10.1111/apt.15029. [DOI] [PubMed] [Google Scholar]
  24. Fang Y., Van Meurs J.B., Bergink A.P., Hofman A., Van Duijn C.M., Van Leeuwen J.P., et al. Cdx-2 polymorphism in the promoter region of the human vitamin D receptor gene determines susceptibility to fracture in the elderly. J. Bone Miner. Res. 2003;18(9):1632–1641. doi: 10.1359/jbmr.2003.18.9.1632. [DOI] [PubMed] [Google Scholar]
  25. Faul J., Kerley C., Love B., O’Neill E., Cody C., Tormey W., et al. 2020. Vitamin D Deficiency and ARDS after SARS-CoV-2 Infection. [PubMed] [Google Scholar]
  26. Frederiksen B., Liu E., Romanos J., Steck A., Yin X., Kroehl M., et al. Investigation of the vitamin D receptor gene (VDR) and its interaction with protein tyrosine phosphatase, non-receptor type 2 gene (PTPN2) on risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY) J. Steroid Biochem. Mol. Biol. 2013;133:51–57. doi: 10.1016/j.jsbmb.2012.08.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Ghodsi M., Keshtkar A.A., Razi F., Mohammad Amoli M., Nasli-Esfahani E., Zarrabi F., et al. Association of vitamin D receptor gene polymorphism with the occurrence of low bone density, osteopenia, and osteoporosis in patients with type 2 diabetes. J. Diabetes Metab. Dis. 2021:1–9. doi: 10.1007/s40200-021-00871-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Gómez J., Albaiceta G.M., García-Clemente M., López-Larrea C., Amado-Rodríguez L., Lopez-Alonso I., et al. Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome. Gene. 2020;762:145102. doi: 10.1016/j.gene.2020.145102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Grant W.B., Lahore H., McDonnell S.L., Baggerly C.A., French C.B., Aliano J.L., et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020;12(4):988. doi: 10.3390/nu12040988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Grasselli G., Zangrillo A., Zanella A., Antonelli M., Cabrini L., Castelli A., et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574–1581. doi: 10.1001/jama.2020.5394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Halsall J., Osborne J., Potter L., Pringle J., Hutchinson P. A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibilty and prognosis in malignant melanoma. Br. J. Cancer. 2004;91(4):765–770. doi: 10.1038/sj.bjc.6602006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Harishankar M., Selvaraj P. Influence of Cdx2 and TaqI gene variants on vitamin D3 modulated intracellular chemokine positive T-cell subsets in pulmonary tuberculosis. Clin. Ther. 2017;39(5):946–957. doi: 10.1016/j.clinthera.2017.04.003. [DOI] [PubMed] [Google Scholar]
  33. Henry B.M., Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int. Urol. Nephrol. 2020:1–2. doi: 10.1007/s11255-020-02451-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Hou Y., Zhao J., Martin W., Kallianpur A., Chung M.K., Jehi L., et al. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Med. 2020;18(1):1–8. doi: 10.1186/s12916-020-01673-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Hribar C.A., Cobbold P.H., Church F.C. Potential role of vitamin D in the elderly to resist COVID-19 and to slow progression of Parkinson’s disease. Brain Sciences. 2020;10(5):284. doi: 10.3390/brainsci10050284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Hussain T., Naushad S.M., Ahmed A., Alamery S., Mohammed A.A., Abdelkader M.O., et al. Association of vitamin D receptor TaqI and ApaI genetic polymorphisms with nephrolithiasis and end stage renal disease: a meta-analysis. BMC Med. Genet. 2019;20(1):1–8. doi: 10.1186/s12881-019-0932-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Hustmyer F.G., DeLuca H.F., Peacock M. Apal, Bsml, Eco RV and Taql polymorphisms at the human vitamin D receptor gene locus in Caucasians, Blacks and Asians. Hum. Mol. Genet. 1993;2(4):487. doi: 10.1093/hmg/2.4.487. [DOI] [PubMed] [Google Scholar]
  38. Ilie P.C., Stefanescu S., Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin. Exp. Res. 2020:1–4. doi: 10.1007/s40520-020-01570-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Imai Y., Kuba K., Rao S., Huan Y., Guo F., Guan B., et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–116. doi: 10.1038/nature03712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Jurutka P.W., Remus L.S., Whitfield G.K., Thompson P.D., Hsieh J.-C., Zitzer H., et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol. Endocrinol. 2000;14(3):401–420. doi: 10.1210/mend.14.3.0435. [DOI] [PubMed] [Google Scholar]
  41. Jurutka P.W., Whitfield G.K., Hsieh J.-C., Thompson P.D., Haussler C.A., Haussler M.R. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev. Endocr. Metab. Disord. 2001;2(2):203–216. doi: 10.1023/a:1010062929140. [DOI] [PubMed] [Google Scholar]
  42. K-i Miyamoto, Kesterson R.A., Yamamoto H., Taketani Y., Nishiwaki E., Tatsumi S., et al. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol. Endocrinol. 1997;11(8):1165–1179. doi: 10.1210/mend.11.8.9951. [DOI] [PubMed] [Google Scholar]
  43. Klein I.A., Rosenberg S.M., Reynolds K.L., Zubiri L., Rosovsky R., Piper-Vallillo A.J., et al. Impact of cancer history on outcomes among hospitalized patients with COVID-19. Oncologist. 2021;26(8):685–693. doi: 10.1002/onco.13794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Kong J., Zhu X., Shi Y., Liu T., Chen Y., Bhan I., et al. VDR attenuates acute lung injury by blocking Ang-2-Tie-2 pathway and renin-angiotensin system. Mol. Endocrinol. 2013;27(12):2116–2125. doi: 10.1210/me.2013-1146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Köstner K., Denzer N., Mueller C.S., Klein R., Tilgen W., Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009;29(9):3511–3536. [PubMed] [Google Scholar]
  46. Kunadian V., Ford G.A., Bawamia B., Qiu W., Manson J.E. Vitamin D deficiency and coronary artery disease: a review of the evidence. Am. Heart J. 2014;167(3):283–291. doi: 10.1016/j.ahj.2013.11.012. [DOI] [PubMed] [Google Scholar]
  47. Laplana M., Royo J.L., Fibla J. Vitamin D receptor polymorphisms and risk of enveloped virus infection: a meta-analysis. Gene. 2018;678:384–394. doi: 10.1016/j.gene.2018.08.017. [DOI] [PubMed] [Google Scholar]
  48. Latini A., Agolini E., Novelli A., Borgiani P., Giannini R., Gravina P., et al. COVID-19 and genetic variants of protein involved in the SARS-CoV-2 entry into the host cells. Genes. 2020;11(9):1010. doi: 10.3390/genes11091010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Lee S.C., Son K.J., Han C.H., Jung J.Y., Park S.C. Impact of comorbid asthma on severity of coronavirus disease (COVID-19) Sci. Rep. 2020;10(1):1–9. doi: 10.1038/s41598-020-77791-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Liu J., Zhang S., Wu Z., Shang Y., Dong X., Li G., et al. Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study. Ann. Intensive Care. 2020;10(1):1–21. doi: 10.1186/s13613-020-00706-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Ma J., Stampfer M.J., Gann P.H., Hough H.L., Giovannucci E., Kelsey K.T., et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol. Prev. Biomark. 1998;7(5):385–390. [PubMed] [Google Scholar]
  52. McNally J.D., Sampson M., Matheson L.A., Hutton B., Little J. Vitamin D receptor (VDR) polymorphisms and severe RSV bronchiolitis: a systematic review and meta-analysis. Pediatr. Pulmonol. 2014;49(8):790–799. doi: 10.1002/ppul.22877. [DOI] [PubMed] [Google Scholar]
  53. Mehrabani S.Z.N., Shushizadeh M.H., Abazari M.F., Aleagha M.N., Ardalan A., Abdollahzadeh R., et al. Association of SHMT1, MAZ, ERG, and L3MBTL3 gene polymorphisms with susceptibility to multiple sclerosis. Biochem. Genet. 2019;57(3):355–370. doi: 10.1007/s10528-018-9894-1. [DOI] [PubMed] [Google Scholar]
  54. Meltzer D.O., Best T.J., Zhang H., Vokes T., Arora V., Solway J. Association of Vitamin D deficiency and treatment with COVID-19 incidence. medRxiv. 2020 [Google Scholar]
  55. Mendy A., Apewokin S., Wells A.A., Morrow A.L. Factors associated with hospitalization and disease severity in a racially and ethnically diverse population of COVID-19 patients. MedRxiv. 2020 [Google Scholar]
  56. Meyer V., Bornman L. Cdx-2 polymorphism in the vitamin D receptor gene (VDR) marks VDR expression in monocyte/macrophages through VDR promoter methylation. Immunogenetics. 2018;70(8):523–532. doi: 10.1007/s00251-018-1063-5. [DOI] [PubMed] [Google Scholar]
  57. Mohammadi A., Azarnezhad A., Khanbabaei H., Izadpanah E., Abdollahzadeh R., Barreto G.E., et al. Vitamin D receptor genetic polymorphisms and the risk of multiple sclerosis: a systematic review and meta-analysis. Steroids. 2020;158:108615. doi: 10.1016/j.steroids.2020.108615. [DOI] [PubMed] [Google Scholar]
  58. Morrison N.A., Qi J.C., Tokita A., Kelly P.J., Crofts L., Nguyen T.V., et al. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367(6460):284–287. doi: 10.1038/367284a0. [DOI] [PubMed] [Google Scholar]
  59. Organization WH . World Health Organization; 2020. Clinical Management of COVID-19: Interim Guidance, 27 May 2020. [Google Scholar]
  60. Ovsyannikova I.G., Dhiman N., Haralambieva I.H., Vierkant R.A., O’Byrne M.M., Jacobson R.M., et al. Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes. Hum. Genet. 2010;127(2):207–221. doi: 10.1007/s00439-009-0763-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Parekh D., Thickett D.R., Turner A.M. Vitamin D deficiency and acute lung injury. Inflamm. Allergy Drug Targets. 2013;12(4):253–261. doi: 10.2174/18715281113129990049. (Formerly Current Drug Targets-Inflammation & Allergy) [DOI] [PubMed] [Google Scholar]
  62. Park S., Lee M.G., Hong S.-B., Lim C.-M., Koh Y., Huh J.W. Effect of vitamin D deficiency in Korean patients with acute respiratory distress syndrome. Korean J. Intern. Med. 2018;33(6):1129. doi: 10.3904/kjim.2017.380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Pranata R., Lim M.A., Huang I., Raharjo S.B., Lukito A.A. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J. Renin-Angiotensin-Aldosterone Syst. 2020;21(2) doi: 10.1177/1470320320926899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Quesada-Gomez J.M., Castillo M.E., Bouillon R. Vitamin D receptor stimulation to reduce Acute Respiratory Distress Syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: revised Ms SBMB 2020_166. J. Steroid Biochem. Mol. Biol. 2020:105719. doi: 10.1016/j.jsbmb.2020.105719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Rhodes J.M., Subramanian S., Laird E., Griffin G., Kenny R.A. Perspective: vitamin D deficiency and COVID-19 severity–plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis. J. Intern. Med. 2020;289(1):97–115. doi: 10.1111/joim.13149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W., et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. Jama. 2020;323(20):2052–2059. doi: 10.1001/jama.2020.6775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Saccone D., Asani F., Bornman L. Regulation of the vitamin D receptor gene by environment, genetics and epigenetics. Gene. 2015;561(2):171–180. doi: 10.1016/j.gene.2015.02.024. [DOI] [PubMed] [Google Scholar]
  68. Shi Y.Y., Liu T.J., Fu J.H., Xu W., Wu L.L., Hou A.N., et al. Vitamin D/VDR signaling attenuates lipopolysaccharide-induced acute lung injury by maintaining the integrity of the pulmonary epithelial barrier. Mol. Med. Rep. 2016;13(2):1186–1194. doi: 10.3892/mmr.2015.4685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Singh A.K., Gupta R., Ghosh A., Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab. Syndr. Clin. Res. Rev. 2020;14(4):303–310. doi: 10.1016/j.dsx.2020.04.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Singhal T. A review of coronavirus disease-2019 (COVID-19) Indian J. Pediatr. 2020:1–6. doi: 10.1007/s12098-020-03263-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Sohrabi C., Alsafi Z., O’Neill N., Khan M., Kerwan A., Al-Jabir A., et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19) Int. J. Surg. 2020;76:71–76. doi: 10.1016/j.ijsu.2020.02.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Tabrizi R., Moosazadeh M., Akbari M., Dabbaghmanesh M.H., Mohamadkhani M., Asemi Z., et al. High prevalence of vitamin D deficiency among Iranian population: a systematic review and meta-analysis. Iran. J. Med. Sci. 2018;43(2):125. [PMC free article] [PubMed] [Google Scholar]
  73. Thickett D.R., Moromizato T., Litonjua A.A., Amrein K., Quraishi S.A., Lee-Sarwar K.A., et al. Association between prehospital vitamin D status and incident acute respiratory failure in critically ill patients: a retrospective cohort study. BMJ Open Respir. Res. 2015;2(1) doi: 10.1136/bmjresp-2014-000074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Tuoresmäki P., Väisänen S., Neme A., Heikkinen S., Carlberg C. Patterns of genome-wide VDR locations. PLoS One. 2014;9(4) doi: 10.1371/journal.pone.0096105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Valdivielso J.M., Fernandez E. Vitamin D receptor polymorphisms and diseases. Clin. Chim. Acta. 2006;371(1–2):1–12. doi: 10.1016/j.cca.2006.02.016. [DOI] [PubMed] [Google Scholar]
  76. van Etten E., Verlinden L., Giulietti A., Ramos-Lopez E., Branisteanu D.D., Ferreira G.B., et al. The vitamin D receptor gene FokI polymorphism: functional impact on the immune system. Eur. J. Immunol. 2007;37(2):395–405. doi: 10.1002/eji.200636043. [DOI] [PubMed] [Google Scholar]
  77. Wacker M., Holick M.F. Sunlight and vitamin D: a global perspective for health. Dermato-endocrinology. 2013;5(1):51–108. doi: 10.4161/derm.24494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Wang W., Zhang W., Zhang J., He J., Zhu F. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019 (COVID-19) Hla. 2020;96(2):194–196. doi: 10.1111/tan.13941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Weir E.K., Thenappan T., Bhargava M., Chen Y. Does vitamin D deficiency increase the severity of COVID-19? Clin. Med. 2020;24(2):e107–e108. doi: 10.7861/clinmed.2020-0301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Whitfield G.K., Remus L.S., Jurutka P.W., Zitzer H., Oza A.K., Dang H.T., et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol. Cell. Endocrinol. 2001;177(1–2):145–159. doi: 10.1016/s0303-7207(01)00406-3. [DOI] [PubMed] [Google Scholar]
  81. Williamson E.J., Walker A.J., Bhaskaran K., Bacon S., Bates C., Morton C.E., et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature. 2020;584(7821):430–436. doi: 10.1038/s41586-020-2521-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Wjst M. Variants in the vitamin D receptor gene and asthma. BMC Genet. 2005;6(1):1–8. doi: 10.1186/1471-2156-6-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Xie M., Chen Q. Insight into 2019 novel coronavirus—an updated intrim review and lessons from SARS-CoV and MERS-CoV. Int. J. Infect. Dis. 2020;94:119–124. doi: 10.1016/j.ijid.2020.03.071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Xu J., Yang J., Chen J., Luo Q., Zhang Q., Zhang H. Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. Mol. Med. Rep. 2017;16(5):7432–7438. doi: 10.3892/mmr.2017.7546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8(4):420–422. doi: 10.1016/S2213-2600(20)30076-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Yancy C.W. COVID-19 and African Americans. JAMA. 2020;323(19):1891–1892. doi: 10.1001/jama.2020.6548. [DOI] [PubMed] [Google Scholar]
  87. Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q., et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int. J. Infect. Dis. 2020;94:91–95. doi: 10.1016/j.ijid.2020.03.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Zdrenghea M.T., Makrinioti H., Bagacean C., Bush A., Johnston S.L., Stanciu L.A. Vitamin D modulation of innate immune responses to respiratory viral infections. Rev. Med. Virol. 2017;27(1) doi: 10.1002/rmv.1909. [DOI] [PubMed] [Google Scholar]
  89. Zemb P., Bergman P., Camargo C.A., Jr., Cavalier E., Cormier C., Courbebaisse M., et al. Vitamin D deficiency and COVID-19 pandemic. J. Glob. Antimicrob. Resist. 2020;22:133–134. doi: 10.1016/j.jgar.2020.05.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Zhang J., McCullough P.A., Tecson K.M. Vitamin D deficiency in association with endothelial dysfunction: implications for patients with COVID-19. Rev. Cardiovasc. Med. 2020;21(3):339–344. doi: 10.31083/j.rcm.2020.03.131. [DOI] [PubMed] [Google Scholar]
  91. Zhang H., Han H., He T., Labbe K.E., Hernandez A.V., Chen H., et al. Clinical characteristics and outcomes of COVID-19-infected cancer patients: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2020 doi: 10.1093/jnci/djaa168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Zheng S., Yang J., Hu X., Li M., Wang Q., Dancer R.C., et al. Vitamin D attenuates lung injury via stimulating epithelial repair, reducing epithelial cell apoptosis and inhibits TGF-β induced epithelial to mesenchymal transition. Biochem. Pharmacol. 2020:113955. doi: 10.1016/j.bcp.2020.113955. [DOI] [PubMed] [Google Scholar]
  93. Zhou X., Xu L.-d., Li Y.-z. The association of polymorphisms of the vitamin D receptor gene with psoriasis in the Han population of northeastern China. J. Dermatol. Sci. 2014;73(1):63–66. doi: 10.1016/j.jdermsci.2013.08.014. [DOI] [PubMed] [Google Scholar]

Articles from Infection, Genetics and Evolution are provided here courtesy of Elsevier

RESOURCES